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Abstract 
Bacteriophage Lambda (λ) has played a historical role as an essential model contributing to our 
current understanding of molecular genetics. Lambda’s major capsid protein “gpD” occurs on each 
capsid at 405 to 420 copies per phage in homotrimeric form and functions to stabilize the head and 
likely to compact the genomic DNA. The interesting conformation of this protein allows for its 
exploitation through the genetic fusion of peptides or proteins to either the amino or carboxy terminal 
end of gpD, while retaining phage assembly functionality and viability. The lytic nature of λ and the 
conformation of gpD in capsid assembly makes this display system superior to other display options.  
 Despite previous reports of λ as a phage display candidate, decorative control of the phage 
remains an elusive concept. The primary goal of this study was to design and construct a highly 
controllable head decoration system governed by two genetic conditional regulation systems; 
plasmid-mediated temperature sensitive repressor expression and bacterial conditional amber 
mutation suppression.  
 The historical λ Dam15 conditional allele results in a truncated gpD fragment when translated 
in nonsuppressor, wild-type E. coli cells, resulting in unassembled, nonviable progeny. I sequenced 
the Dam15 allele, identifying an amber (UAG) translational stop at the 68th codon. Employing this 
mutant in combination with a newly created isogenic cellular background utilizing the amber 
suppressors SupD (Serine), SupE (Glutamine), SupF (Tyrosine) and Sup— (wild type), we sought to 
control the level of incorporation of undecorated gpD products. As a second dimension, I constructed 
two separate temperature-inducile plasmids whereby expression of either D or D::eGFP was 
governed by the λ strong λ CI[Ts]857 temperature-sensitive repressor and expressed from the λ PL 
strong promoter.   
 Our aim was to measure the decoration of the λ capsid by a D::gfp fusion under varying 
conditions regulated by both temperature and presence of suppression. This was achieved utilizing 
this controllable system, enabling the measurement of a variable number of fusions per phage based 
on diverse genetic and physical environments without significantly compromising phage viability. 
Surprisingly, both SupE and SupF showed similar levels of Dam15 suppression, even though 
sequencing data indicated that only SupE could restore the native gpD sequence at amino acid 68 (Q). 
In contrast, SupD (S), conferred very weak levels of suppression, but imparted an environment for 
very high decoration of gpD::eGFP per capsid, even at lower (repressed) temperatures. The presence 
of albeit few wild-type gpD molecules allowed for an even greater display than that of the perceived 
“100%” decoration scenario provided by the nonsuppressor strain. It appears that the lack of wild-
type gpD does not allow for the space required to display the maximum number of fusions and in turn 
creates an environment that affects both phage assembly and therefore phage viability. Finally, the 
use of Western blotting, confirmed the presence of gpD::eGFP fusion decoration by employing a 
polyclonal anti-eGFP antibody.  
The significance of this work relates to the unique structure of λ’s capsid and its ability to 
exploit gpD in the design of controlled expression, which is guiding future research examining the 
fusion of different therapeutic peptides and proteins. Furthermore this approach has important 
implications specifically for the design of novel vaccines and delivery vehicles for targeted gene 
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therapy in which steric hindrance and avidity are important concerns. 
The execution of this project employed basic bacterial genetics, phage biology and molecular 
biology techniques in the construction of bacterial strains and plasmids and the characterization of the 
phage display system. 
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Chapter 1 General Introduction 
1.1 Discovery of Bacteriophages and Bacteriophage λ 
The term Bacteriophage (phage) was first derived from the word bacteria and the Greek word phagein 
meaning "to eat". Phage number in the range of 1031 total on the planet and have long been exploited 
as a founding piece in the fields of molecular and microbial biology. Simply defined as viruses that 
infect bacteria, they have been part of a continuing dialogue throughout the last century (d'Herelle, 
Smith 1926). Discovered independently in 1915 and 1917 by two separate researchers; British 
bacteriologist Frederick Twort and French-Canadian microbiologist Félix d'Hérelle, phage have 
continued to play a significant role in our early understanding of microbial genetics (d'Herelle, Smith 
1926, Twort 1915, Duckworth 1976).  
 One of the first papers published on bacteriophages (Twort, 1915) described what he called 
“ultra-microscopic viruses”. His initial experiments involved the filtration of phage, where he found it 
difficult to obtain proof of their existence aside from their antibacterial effects and was unable to 
show growth on many types of media or show the infection of a variety of different animal species. 
Here he also recorded the first observation of plaques, which he explained as “transparent colonies” 
(Twort 1915). 
 In 1926 d'Hérelle published a book entitled “The Bacteriophage and Its Behavior”, where he 
examined many aspects of phage and recounted his discoveries in using phage to treat dysentery. He 
chronicled these stories in “On an Invisible Microbe Antagonistic to Dysentery Bacteria", where he 
ran into many of the initial culturing problems of Twort (Duckworth 1976, d'Herelle, Smith 1926). 
D'Hérelle makes reference to the work done by Twort, and the use of ultrafiltration and presence of 
plaques referring to them as “dissolution of the bacterial cell”. D'Hérelle also examined the minimum 
and maximum amount of bacteriophage required to induce “bacteriophagy” and went on to test the 
effects of many substances and conditions on viability of phage (d'Herelle, Smith 1926).  
 Among the earliest studies of phage, bacteriophage λ has played an essential role in the 
development and understanding of bacterial genetics and has long been used in the development of 
biological tools. Decades after phage were first isolated, the structure of λ was beginning to be 
understood using electron microscopy, it was also determined that if phage were heated or dialyzed 
against a chelating agent, they would eject their DNA, resulting in particles referred to as ghost 
particles. It was through work using electron microscopy that A.D. Kaiser (1966) was able to 
determine the structure, the capsid size and shape and the genomic compaction of λ DNA, which led 
him to suggest the hypothetical structure of the phage, which consists of a coat and a core that was 
surrounded by DNA. He commented on the geometric shape of a phage and the appearance of the tail 
structure, which is not very dissimilar from the head structure that we know today, comprised of an 
outer coat, DNA wrapped around a core and a tail (Kaiser 1966).  
 
 
  2 
1.1.1 Bacteriophage λ Capsid Morphology and Major Capsid Protein gpD 
The capsid of λ was determined to be icosahedral in shape, approximately 60 nm in diameter, with a 
shell thickness of 4 nm that accommodates a genome of approximately 47 kb in length (Witkiewicz, 
Schweiger 1982, Hohn, Katsura 1977). Empty, the capsid has a molecular weight of 21 x 106 
Daltons;the genome adds an additional 31 x 106 Daltons (Hohn, Katsura 1977).  
Phage λ’s capsid is made up of two major proteins, gpE and gpD, arranged in a hexagonal 
lattice in equimolar quantities, where the bottom side of gpD binds to the gpE arrangement (Wurtz, 
Kistler & Hohn 1976, Yang et al. 2000). The gpD, capsid protein has a molecular mass of 11.4 kDa, 
and like its counterpart gpE is present in approximately 405-420 copies in a mature phage head as 
strongly protruding thimble-shaped trivalent spikes. Unlike its arrangement on the mature capsid, λ 
major capsid proteins exist as monomers in solution (Mikawa, Maruyama & Brenner 1996, 
Witkiewicz, Schweiger 1982, Dokland, Murialdo 1993, Yang et al. 2000). GpD function is related to 
the stabilization of the phage head as it fills with DNA and is essential for phage head morphology, 
but only when packaged with a full-length wild-type genome (Mikawa, Maruyama & Brenner 1996, 
Sternberg, Hoess 1995, Lankes et al. 2007). In the absence of gpD only mutants packaging less than 
82% of DNA can form mature phage (Sternberg, Hoess 1995, Mikawa, Maruyama & Brenner 1996, 
Katsura 1983, Imber et al. 1980, Sternberg, Weisberg 1977). The gpD protein possesses similar 
properties to eukaryotic chromosomal proteins and has been shown to cross-react immunologically 
with eukaryotic histones (Witkiewicz, Schweiger 1982). This similarity may further help to predict 
gpD’s function involving the stabilization and compaction of phage DNA. One such study replaced D 
with phage 21’s shp gene, which is homologous to D and shares 49% amino acid identity. Results 
showed that shp can stabilize the λ head shell, but virions were strictly dependent on the presence of 
Mg2+ and were very sensitive to chelating agents (Wendt, Feiss 2004).  
 
Figure 1: Single face of Bacteriophage Lambda displaying major capsid proteins gpD and gpE 
Schemtic of a single face of λ illustrating the arrangement and position of the two major capsid proteins, gpD 
(arranged in trimers) and gpE (arranged in hexamers). Approximately 405-420 copies of each protein are found 
per capsid.   
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1.2 Initial Phage Display 
Phage display is defined as the “process by which a peptide or protein is expressed as an exterior 
fusion to a surface protein of the phage particle” (Lindqvist 2005). This revolutionary technique is 
based on the genetic fusion, which creates a physical link between phenotype, where the fused protein 
is expressed on the phage coat and genotype where its corresponding gene is inserted into the phage 
genome (Jestin 2008). The first indications that phage could potentially be used as display vectors 
came from the work of Makela and Haimovich and Sela in the mid 1960s. Makela et al. (1966) was 
able to couple phage T2 with 3-iodo-4-hydroxy-5-nitrophenylacetic acid chloride (NIP) and then 
inactivate the phage with an anti-NIP antibody while working to produce a sensitive assay for an anti-
hapten antibody. It was found that a very low concentration of antibody was required to inactivate the 
coupled phage. In a similar study Haimovich and Sela were able to react phage T4B with N-earhoxy-
DL-alanine anhydride to yield poly-DL-alanyl bacteriophage and then inactivate the phage antisera 
(Haimovich, Sela 1969a). Haimovich and Sela were also able to demonstrate the covalent attachment 
of proteins to phage T4 employed to quantitatively measure the antigens and detect their antibodies 
(Haimovich, Sela 1969b). This application is of major importance to phage display in current research 
since the ability to fuse foreign molecules especially antibodies to the phage coat has greatly 
increased the ability to scan large peptide libraries and identify novel binding targets. However, the 
techniques to append these foreign molecules to the surface of the phage have become much more 
advanced since the time of this initial study (Vaccaro et al. 2006)  
The first evidence of a translational capsid gene fusion was observed by G.P. Smith (1985) 
when he successfully inserted an external gene into a phage genome. This construct consisted of the 
EcoRI endonuclease gene product being displayed on the filamentous phage fd minor coat protein 
pIII (Smith 1985). Based on this research it was envisioned that lytic and temperate phage could 
potentially be used as fusion vectors and this premise has since been explored (Garufi et al. 2005). 
The lytic phages T4 and T7 and the temperate phage λ, have been shown to express both amino or 
carboxy terminal fusions to major and/or minor capsid proteins (Lindqvist 2005).  
While filamentous phages are not a focus of this study, the principles of their early use 
govern phage display advances, and hence, are worth reviewing here. The most extensively used 
phage are derived from the E. coli Ff  (filamentous) class, where the most commonly explored species 
include M13, fd and f1. The basic structure of these phage consists of a circular single stranded DNA 
genome that is encased in a long tube composed of thousands of copies of a single major coat protein 
with four additional minor capsid proteins at the tips. The two major coat proteins are pVIII and pIII 
respectively, where the most common fusions to these proteins are N-terminal and the average phage 
can be found to have approximately 2700 copies of pVIII and 3-5 copies of pIII, depending on the 
size of genome. Traditionally filamentous phages require the use of a phagemid or helper phage to 
participate in phage display of foreign peptides or proteins. A phagemid is a hybrid of a phage and 
plasmid vector, where it contains two origins of replication (one from the phage and one from the 
bacterial host), one of the coat proteins, a multiple cloning site and an antibiotic resistance gene, but 
lacks all other phage genes that encode structural and non-structural proteins required to produce a 
viable phage. These phagemids can then be grown as plasmids in a bacterial cell and packaged with 
the aid of a helper phage, which provides the remainder of the necessary machinery to produce 
functional phage (Mullen et al. 2006). In addition to the use of phagemids and helper phage, 
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filamentous display systems, usually also employ peptide linkers in between the foreign peptides and 
the coat protein, so that the recombinant can maintain its native structure and function normally; the 
phage protein acts only as an anchor (Bratkovic 2010).   
Initially, phage display was developed to create  phage display libraries. Two types of 
libraries are commonly created: random peptide libraries and natural peptide libraries. Peptide 
libraries contain synthetic random degenerate oligonucleotide inserts that are used almost exclusively 
to identify linear antigenic epitopes. These have a universal nature and are used for many 
applications. Natural peptide libraries on the other hand are composed of randomly fragmented DNA 
from the genomes of selected organisms. These libraries are important alternatives to the random 
peptide library that are used for identification of vaccine components and bacterial adhesins but 
unfortunately the majority of clones are nonfunctional, since many are not in the correct orientation or 
coding frame (Mullen et al. 2006).   
While filamentous phage played an essential role in the establishment of phage display and 
their application in biotechnology, they possess some major limitations that are overcome by lytic 
display. Firstly, they require the fusion to be translocated across the plasma membrane and therefore 
many hydrophilic cytoplasmic proteins cannot be extruded as fusion proteins. Secondly, there is a 
significant limitation to the size of fusions (Garufi et al. 2005, Mikawa, Maruyama & Brenner 1996, 
Sternberg, Hoess 1995) and thirdly, filamentous phage do not cause lysis or loss of viability to the 
host, which can be detrimental if the fusion is a toxic molecule and could prove harmful to the host 
when expressed in large quantities. Toxicity exists when the fusion is expressed in large quantities 
because the filamentous phage lifecycle does not lyse the cell (individual phage bud from the host) 
which would not allow high concentrations of toxic molecules to accumulate within the cell (Garufi et 
al. 2005). Due to the lytic nature of vegetative growing phage, the fusion of toxic proteins to lytic 
phage is no longer a concern in temperate or lytic double stranded (ds) DNA bacteriophage since they 
are repressed in the phage lysogenic state and are only expressed just prior to cell lysis (Garufi et al. 
2005). 
Soon after the finding that λ could be used in phage display, subsequent studies revealed 
other interesting phage platforms. The C-terminus of the minor T4 fibrous structural protein fibritin 
that builds the collar/whiskers complex on the neck of the phage, and the C-terminus of the T4 minor 
capsid proteins HOC and SOC were also found to tolerate fusions for phage display (Ren et al. 1996, 
Efimov, Nepluev & Mesyanzhinov 1995). More recently, phage T7 has also been used as a display 
platform for various GFP-based cytoplasmic proteins that showed poor expression (fluorescence) 
with more traditional filamentous display vectors (Dai et al. 2008). Though it was important to study 
the ability of lytic phages to display foreign proteins on their surfaces, the use of temperate phage λ as 
a display vector was investigated further.  
 Santini et al. (1998) developed a chimeric phage system in which C-terminal fusions to 
lambda’s gpD were made. In this work, recombinant phage were decorated with both wild-type D and 
proteins from a hepatitis C virus (HCV) cDNA expression library and these recombinant phage were 
compared to two other libraries utilizing the cDNA expression library: N-terminal fusions to the pIII 
and pVIII capsid proteins of M13. HCV was chosen for this study because the immune response in 
humans has been heavily studied. With regard to the cDNA library, the majority of the inserts were 
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between 100 to 300 bp in length. In order to avoid the possibility of lambda phage containing only 
wild-type gpD, the vector used contained a second copy of the D gene that carried an amber mutation, 
and therefore the library was plated on an amber suppressor (BB4) allowing for the formation of 
chimeric phage. When comparing filamentous phage proteins, pVIII’s display was more efficient then 
pIII, and when pVIII was compared to gpD display and selection of protein fragments of limited size, 
the two libraries showed comparable efficiencies. When larger protein fragments were tested, gpD 
outperformed pVIII. This can be attributed to the fact that λ does not require secretion of the fusion 
protein, and therefore unlike pIII/VIII, larger recombinant proteins can fold properly; do not interfere 
with phage assembly, and are displayed in higher densities. Non-homogeneous ligates such as human 
HCV-positive sera could also be used to identify positive phage after a single round or a few rounds 
of selection when utilizing λ. This level of specificity can be exploited to identify common 
immunodominant antigens in the development of new vaccines (Santini et al. 1998).    
 Gupta et al. (2003) designed a lambda phage display vector that expressed fusions on the C-
terminus of gpD. This library was compared an M13 phage library involving N-terminal fusions to 
the major and minor coat proteins PVIII and PIII, respectively. The λ library displayed a 100-fold 
higher display for all fragments compared to filamentous phage when tested using an antibody-
binding assay. In addition, no degradation of displayed products was observed, a consequence that is 
common when using M13. Overall, the λ system was able to display proteins of different sizes, with 
the number of fusions displayed on each phage particle being 2-3 orders of magnitude greater than 
that of M13. This high-density display became very powerful when applying it to epitope mapping; 
the λ system far outperformed M13, based on its higher ELISA reactivity. (Gupta et al. 2003)  
1.3 λ Phage Display 
One key finding that indicated interest in the use of temperate phage (λ) in an industrial setting was a 
patent filing in 1982, where a commercial approach was taken for the use of these modified 
molecules. In the claims it is suggested that a new strategy for vaccine production was possible where 
the foreign particle function would be preserved as well as the maintenance of viral replication. The 
system would then elicit an immune response in vivo (Dulbecco 1982). This filing helps to support 
the continuation of this type of research study and gives justification for its further downstream 
development and potential commercialization.  
Early experiments of λ-fused peptides were conducted by fusing the peptide or protein of 
interest to the carboxy terminus of the major tail protein gpV. The initial display vector employed the 
carboxy terminus because this end of the protein faces outward and has previously been shown to be 
non-essential and therefore free to accept fusions. Dunn also demonstrated that λ gpV tolerated large 
multimeric proteins such as, β-galactosidase, but that the incorporation of fusions as well as the yield 
of phage after affinity chromatography was very low at approximately one copy per lambda tail tube 
and one percent recovery, respectively (Dunn 1995).  
While the main application for phage display remains the screening of cDNA libraries, other 
more clinical applications include: antibody engineering, epitope mapping, tumour targeting, 
diagnostic development, identification of protein-protein interactions and drug development 
(Petrenko 2008).  
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1.3.1 Fusion to Major Capsid Protein gpD 
To overcome the copy limitations imposed by gpV-mediated fusions, fusions to the major capsid 
protein gpD were investigated. gpD’s incorporation to the λ capsid was ideal for fusions since both its 
amino and carboxy termini protrude outward (Mikawa, Maruyama & Brenner 1996, Witkiewicz, 
Schweiger 1982). Mikawa et al. (1996) determined that both the N and C termini of gpD are neither 
at the trimer interaction interface nor do they interact with the other major capsid protein gpE and that 
terminal tolerance and capacity depends on the peptide/protein that is fused. Subsequent studies 
demonstrated that gpD was tolerant of peptide and protein genetic fusions at either its N- or C- 
termini (Sternberg, Hoess 1995). Thus, the system could be used to detect binding of relatively low-
affinity ligands and has the potential to be exploited to pan epitope libraries as a high avidity gene 
delivery vehicle.  
Two unique vector features used in these initial constructs included a peptide linker and the 
use of conditional fusions via amber suppression strategies that permitted the fusion of multimeric 
proteins. Suppression was used as a crude control mechanism for capsid fusion expression, which was 
attempted by employing various allogenic E. coli suppressor strains, only a slight difference of 
expression was observed (SupE, SupF, SupG, Sup—) (Maruyama, Maruyama & Brenner 1994, 
Mikawa, Maruyama & Brenner 1996). These strains allowed differing levels of expression of gpD 
due to the presence of mutations in the tRNA genes of the E. coli strains in which the phage were 
grown.  
 A B 
Figure 2: Schematic of Amber Suppression  
The above schematic illustrates the concept of suppression as it pertains to the Dam15 mutation within λF7. A. 
When λF7 is grown on a suppressor strain an amino acid is inserted instead of a termination signal, gpD is fully 
translated and a viable phage is produced. B. In the absence of suppressor, gpD is truncated and a non-viable 
phage is produced. Sequencing of λDam15 determined a point mutation in the 68th codon (CAG) of gene D 
encoding Glutamine (Q), to an amber stop codon (UAG), this agrees with historical literature that demonstrates 
that supE is the strongest suppressor.  
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Amber suppression. The genetic phenomenon of suppression is mediated by mutant alleles of 
tRNA’s that possess an anticodon mutation. This is complementary to a stop codon that results in the 
insertion of an amino acid in response to reading a termination nonsense codon as sense, thus 
relieving the translational truncation imparted by the original nonsense codon. In this study, a 
bacteriophage containing an amber stop codon within its D gene is suppressible on a mutant bacterial 
strain (Sup+) that recognizes and decodes the termination signal with an amino acid, resulting in a 
non-truncated, full length 110 amino acid (a.a.) protein (Figure 2). Depending on the termination 
signal that is suppressed the suppression can either be amber (UAG), ochre (UAA), or opal (UGA). 
Amber suppressors are the focus of this study. These are suppressible by mutant E. coli strains that 
recognize and code the UAG stop signal as sense. Permissive hosts are considered suppression 
positive (Sup+) and non-permissive hosts are correspondingly suppression negative (Sup—). If a 
variety of permissive hosts suppress the same type of stop codon then they belong to the same class 
(amber suppressors, AS, suppress the UAG stop codon), but based on the AS allele, may insert a 
different amino acid into the peptide chain at an encountered stop signal. The amber suppressor 
tRNAs that have been created in vivo include serine, glutamine, tyrosine and leucine; this study used 
serine (supD), glutamine (supE) and tyrosine (supF), respectively. In permissive strains both the 
terminated and completed peptide chain are produced, with the efficiency of suppression being 
dependent on which suppressor is carried by the bacterial strain (Brenner, Stretton & Kaplan 1965, 
Sarabhai et al. 1964). It is proposed that the supD amber suppressor was created by a single random 
nucleotide change in the anticodon from CGA (serine) to CUA, the anticodon that reads UAG 
(amber) stop codons (Steege 1983). The supE suppressor has been found to exist in two species 
(tRNA1Gln & tRNA2Gln). The tRNA2Gln suppressor was used in this research. It maps at 15 min on the 
E. coli chromosome, near the integration site of λ, thus complicating transduction of this gene. SupE 
is derived from a single base change again at the 3ʹ′ end of the anticodon altering the recognition from 
glutamine to amber stop (CUG to CUA) (Inokuchi et al. 1979). The third suppressor used in this 
research, supF encodes tyrosine in the place of UAG and is again derived from a single point 
mutation, this time a switch from GUA to CUA, allowing a tyrosine to be inserted upon reading the 
amber stop codon. Although all amber suppressors operate at different strengths, they are still 
superior to ochre suppressors. Moreover, although their complete function is not fully understood, 
they do allow for the expression of modified proteins in a controlled fashion when a permissive host 
is present, which has become very useful during the construction of this phage capsid display 
platform (Goodman et al. 1968).      
1.3.2 Application of Phage Display in Phage Therapy 
Many different applications of phage display have been employed throughout the years, with the 
system remaining essentially the same, but the number of applications steadily increasing. Vaccines 
represent one such important application. Bastien et al. (1997) investigated the use of a recombinant 
fd phage displaying the glycoprotein G of the human respiratory syncytial virus (RSV).  
 One of the major concerns surrounding λ display is the available screening for in-frame 
fusions especially when display is employed to screen cDNA libraries for novel compounds. Santini 
et al. (1998) constructed and characterized a HCV cDNA expression library displayed as a fusion to 
the C-terminal of gpD along with wild-type D creating a chimeric phage collection. This was used to 
 
  8 
screen for anti-HCV human monoclonal antibodies recognizing linear or conformational epitopes, 
and antibodies from human sera from HCV-infected patients. The generated lytic display libraries 
were then also compared to similar libraries created using filamentous phage M13 (Santini et al. 
1998). To increase the complexity of their screening system the same group also constructed two 
additional λ libraries, one containing total RNA from the human adult brain and the other made of 
total mouse embryos RNA and were able to show that fused polypeptides are specifically and very 
efficiently selected by using monoclonal antibodies and affinity selection (Santi et al. 2000).  
 The screening process has since been taken one step further, to target specific cells. Curiel et 
al. (2004) used a phage display library to identify specific dendritic cell binding peptides, which were 
then fused to a structural protein of hepatitis C virus for display to naive CD4+ and CD8+T cells. 
This work represents a novel way to use phage for vaccine development (Curiel et al. 2004).  
 Examples of proteins/peptides that have been fused to λ include: human peroxisome 
proliferator-activated receptor γ (Kong, Ma 2006), scFv antibodies (Vaccaro et al. 2006), β-
galactosidase, β-lactamase and IgG-biding domains of the Staphylococcus aureus protein A (Mikawa, 
Maruyama & Brenner 1996), tumor-associated antigens (Minenkova et al. 2003) and autoantigens 
from HeLa and HepG2 cells (Niwa et al. 2000). 
In order to simplify the process of screening cDNA libraries, specific vectors have been 
created that have been designed to readily accept in-frame fusions that will expedite the phage display 
library construction. Two such vectors are the λD-bio vector and the λKM phage The λD-bio vector 
utilizes the host encoded biotin ligase (Bir A) by placing its biotinylation target downstream of the C-
terminal cloning site of gpD (Ansuini et al. 2002). By employing this construct only those fusions that 
are in frame with the target sequence are biotinylated (in vivo and in vitro) and are then selected by 
affinity chromatography with the high-affinity biotin ligand, streptavidin. The λKM phage possess; 
two unique cloning sites, a two-gene system of genomic D and Dam and a GS linker to maintain 
fusion-folding integrity. One phage is designed to accept N-terminal D fusions (λKM8) and the 
second designed for C-terminal fusions (λKM10) (Pavoni et al. 2004).  
In recent years phage therapeutic practices also include the use of a T7 and λ for phage 
display to identify antigens eliciting B cell responses in cancer patients. Isolates were then tested for 
their suitability to develop a microarray system (Kalnina et al. 2008). Two important recent 
therapeutic applications of phage display include a study where phage display was employed for in 
vivo targeted gene therapy involving the heart vasculature (Nicol et al. 2009); the second utilized 
phage display to screen for potential peptides with the ability to transport molecules to the brain via 
the nasal passage—a viable approach in order to bypass the blood-brain barrier (Wan et al. 2009). 
While both of these studies utilized systems based on filamentous phage M13, a related study 
described the use of phage λ displaying the HIV-1 Tat peptide on the phage surface and carried 
mammalian marker genes in its genome was conducted (Eguchi et al. 2001). The presence of the TAT 
protein appears to increase the likelihood of gene transfer across the plasma membrane of mammalian 
cells, which could give insight into future gene delivery strategies (Eguchi et al. 2001).  
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1.4 Phage Therapy 
While phage may be exploited for a wide array of therapeutic applications, their initial and most basic 
use employed their natural attributes as powerful and malleable antibacterials that co-evolve with 
their host(s). Here I examine one application, termed phage therapy. 
An initial study that gave insight into the potential use of λ as a therapeutic explored the use 
of this phage for the elimination of foreign particles in a tissue-specific manner from non-immune 
germ-free animals. Geier et al. (1973) examined the accumulation of phage in various organs after 
intraperitoneal, intravenous and intramuscular administration. Although all organs studied contained 
viable phage, the spleen contained the highest titres with generally higher titres upon intraperitoneal 
injection. The overall observation that phage are quickly eliminated through the immune system of 
intact animals would become important in future studies examining the ability of phage to be used in 
the development of biologics and as a gene delivery tool (Geier, Trigg & Merril 1973). 
 With the evolution of phage display, the question that remains is, for what benefit can this 
technique be used therapeutically? One of the most prominent ideas for temperate and lytic phage 
display is their use in the generation of novel antibacterials, leveraging the natural action of phage for 
lysis of the host cell. One of the first studies that demonstrated the use of bacteriophage as 
therapeutics was done by Smith and Huggins in 1982. They showed that a single intramuscular dose 
of anti-K1 phage against an E. coli strain was more effective than multiple intramuscular doses of 
various antibiotics in curing mice of a potentially lethal intramuscularly or intracerebrally induced 
infection and was at least as effective as multiple intramuscular doses of streptomycin (Smith, 
Huggins 1982). Furthermore, it has been suggested that phage themselves can direct us towards novel 
bacterial protein targets for the development of new antibiotics, if we study their native strategies 
(Brown 2004). One such study that provides support for this theory sequenced 26 Staphylococcus 
aureus phages and identified 31 novel polypeptide families that inhibited host cell growth upon 
expression and could potentially be used as antibacterials, targeting vital components of host cell 
machinery (Liu et al. 2004).  
 Phage were used as antibacterials in many countries even before the advent of antibiotics. 
Today in some countries like the former Soviet Union, phage therapy is still employed to treat 
infections. In addition to human treatment, the use of phage in animal industries is also being 
explored (Coates, Hu 2007, Kropinski 2006). With the current status of antibiotics and antibiotic 
resistant strains, many companies are revisiting the use of phage as therapeutics. Countries such as 
Georgia, Poland, Germany, Portugal, Israel, UK, USA and Canada, have research programs based on 
the use of phage (Kropinski 2006). Even though there is much interest in using phage commercially 
the main research and practice regarding phage therapy is happening at Eliava Institute in Tbilisi 
(Georgia) and the L. Hirszfeld Institute of Immunology and Experimental Therapy in Wroclaw 
(Poland). The use of phage is a very promising alternative to the dilemma facing the future of 
infectious disease; but there is still a great deal to investigate. The principal concerns associated with 
phage therapy are safety and efficacy, particularly integration, resistance, and long-term effects and 
consequences on commensal biota and host specificity (Gorski, Weber-Dabrowska 2005). Additional 
questions and caveats include large-scale production where the best storage and transportation 
practices need to be determined; and human clinical trials, where the lack of data and potential for 
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exploration in children is still not well understood (Fortuna et al. 2008); lack of information regarding 
the pharmacokinetics of phage and discussions surround giving phage orally; phages ability to reach 
their site of action including the ability to cross the blood-brain barrier; and their preferential use of 
passive or active therapy modalities still needs much exploration (Brussow 2005).  
 To increase the quality control and standardization of phages for use as therapeutics, studies 
examining their applicability to be stored and transported have been reported. Jepson and March 
(2004) examined many aspects that could potentially affect the commercialization of new phage λ 
therapeutics. These included examining phage half-life, freeze-thaw stability, stability of desiccated 
phage, stability of liquid phage stocks, stability of phage in water, and effect of pH on phage stability. 
In general, they discovered that most phage were found to be highly stable under normal storage 
conditions and oral administration of phage DNA vaccines via drinking water may even be possible 
(Jepson, March 2004). 
 Potential uses for phage therapy range from decontamination of surfaces and/or environment, 
carcass treatment, use in the treatment of plants, aquaculture, animals and humans in an oral, 
intravenous or topical manner. More broad uses include; phage as vaccine delivery vehicles, targeted 
gene-delivery and for the detection and typing of bacteria (Clark, March 2006). In addition, Gorski et 
al. (2009) examined the use of phage therapy for the treatment of infections as they relate to the 
overall burden produced by current antibiotics. They discuss many of the issues and benefits of phage 
therapy as well as describe the massive repertoire of therapeutic phages housed by the Institute of 
Immunology and Experimental Therapy in Poland, where phage therapy has been conducted along 
with the distribution of therapeutic phages since 1952. In 2005 an outpatient clinic was even 
established there. One of the surprises surrounding phage therapy is the presence of many clinical 
trials taking place all over Europe, where one such formulation (PhageBioDerm) has been licensed 
for use since 1999 (Gorski et al. 2009).  
1.5 Controllable Phage Display Systems 
Although significant applications have been derived from the original work on lytic display, control 
of fusion copy number has generally remained quite crude. The use of amber suppression to regulate 
gpD fusions was first introduced by Mikawa et al. (1996) and represents the only rudimentary 
regulation system to date. This approach was allogeneic, qualitative and based on relative display.  
Elegant and more modern approaches have been employed to generate gpD fusions in vivo, to 
generate libraries and purify functional fusions, and to increase the size and density of capsid fusions, 
but the issue of copy control that may have an important impact upon the different applications of this 
technology has yet to be resolved (Lankes et al. 2007). Variation in the number of fusions per phage 
particle does indeed occur, which is dependent upon the size of the fused fragment, whereby the 
smaller the fragment the greater the number of fusions per phage (Gupta et al. 2003). Since a 
differentiation in fusion number naturally exists, when comparing strategies for the development of a 
vaccine versus a vector for gene delivery or fusion of a peptide versus a large multimeric protein, 
vastly different approaches must be taken. In addition, the occurrence of overstimulation of a signal 
due to high affinity or high avidity interactions and the possibility of cross-reactivity and steric 
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hindrance impeding protein function or ligand access are also considerations that must be taken into 
account depending on the desired downstream application. 
Since the initial lytic phage display design studies, there has been little attention paid to 
improving expression control, rather the focus has remained upon development of novel therapeutic 
or industrial applications for the system. Newer application studies that combine the genomic 
flexibility of phage with phage display pave the way however, for a powerful bimodal strategy that 
employs phage display in combination with genomic modifications for targeted gene delivery 
systems. Lankes et al. (2007) were the first to report the potential of phage manipulation for gene 
transfer in vivo, showing increased cellular uptake of a λ phage, modified to express firefly luciferase 
enzyme (luc), in mammalian cells by displaying an integrin-binding ligand domain on the surface of 
the phage to target CD51/CD61 receptors that mediate efficient endocytosis on the surface of 
dendritic cells. The incorporation of control over fusion decoration is a paramount concept toward the 
development of phage display therapeutics for clinical applications.  
1.6 This Research  
The primary goal of this work was to construct and characterize a λ phage display system that enables 
rigorous control of phage capsid fusion copy number. In order to achieve this goal, phage λ with an 
amber mutation in the major capsid protein, gpD, C-terminally fused to eGFP for ease of detection, 
was exploited. A bacterial system that contained two genetic systems for inducible control was used: 
host cell amber suppression and plasmid-encoded, repressor-mediated temperature sensitive 
repression. In the past, phage λ has been shown to accommodate C-terminal gpD fusions, but 
decorative control was never a focus.  
1.6.1 First Level of Control: Conditional D expression via Amber Suppression 
As previously introduced, “amber suppression” is a genetic conditional expression process whereby a 
nonsense codon is read by a complementary mutant tRNA of E. coli host, the binding leads to the 
insertion of an amino acid in place of the UAG stop signal tRNA (Benzer, Champe 1962). This 
conditional expression strategy was also applied to bacteriophage T4D, where nonsense mutations 
within the head protein were suppressed to produce a fragment of the polypeptide chain in the 
presence of a suppressor host (Sup+) (Sarabhai et al. 1964). It was through this initial research that 
further inferences were made to predict that codons UAG and UAA were chain terminators and that 
in the presence of a permissive cell (Sup+) they could be suppressed and propagation observed, albeit 
at a lower frequency. Correspondingly, in a nonpermissive cell (Sup—) the amber mutations were not 
suppressed and propagation was absent. Furthermore, there was also a switch in amino acid observed 
from the wild-type sequence and different types of suppressors existed (amber, ochre) depending on 
the triplet present in the sequence and in fact different suppressor strains did exist for each and were 
mutually exclusive (Brenner, Stretton & Kaplan 1965). One caveat of amber suppression is the ability 
to restore original sequence functionality. With suppression, two levels of protein function occur: 
non-functional fragments of the protein in addition to full-length functional species. To increase the 
efficiency of suppressors, it has been proposed that these are created through total gene synthesis, 
where the inserted amino acid is equivalent to the wild type (Normanly et al. 1986).  
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1.6.2  Second Level of Control: Temperature-inducible Fusion Expression 
The λ cI[Ts]857 temperature-labile repressor has long been used to regulate downstream gene 
expression. Lieb (1966) first characterized the temperature-mediated lability of this protein, and 
discovered that it was the dissociation of this repressor complex that allowed downstream 
transcription to proceed (Lieb 1966, Szybalski et al. 1969). It is the controllable nature of this 
repressor, associated with its expression from a strong promoter that has made temperature-sensitive 
cI[Ts] alleles attractive for use in cloning vectors. In these cases a single copy of the c1[Ts] gene 
produces enough repressor to completely inhibit the strong λ PL or PR promoter, whether on single or 
multicopy replicons (Bernard et al. 1979, Remaut, Stanssens & Fiers 1981). Under this promoter’s 
control, a downstream gene is expressed at increasing levels as temperature rises due to one of the 
two lesions. First,the cI857 allele  confers thermal sensitivity. Even though this high-level expression 
strategy may not be as effective as chemical induction approaches, it is less likely to be genotoxic and 
provides controllable expression—attributes that comparatively are far more advantageous. The 
second lesion termed Ind-, renders the cI857 repressor resistant to inactivation by the RecA protein, 
which when active can act as a protease and autocatalytically cleave the repressor (Mott et al. 1985, 
Villaverde et al. 1993). The cI857 allele is most unstable at its denaturation point of 40-42° C, where 
maximal expression is thought to be observed (Hayes, Hayes 1986). Conversely, temperatures as low 
as 29° C may be required to fully repress transcription from PL via the cI857 allele, and highest 
protein yields can be obtained following induction at 36° C, but the latter temperature and its 
efficiency is still dependent on the protein being expressed and the host cell as the expression of many 
heterologous proteins innately affects bacterial cell growth and survival (Lowman, Bina 1990, 
Villaverde et al. 1993, Guzman et al. 1994, Jechlinger et al. 1999).  
Strategies to avoid protein expression toxicity include: i) suppression of basal expression 
from leaky inducible promoters; ii) suppression of read-through transcription from cryptic promoters; 
iii) tight control of plasmid copy numbers; iv) protein production as inactive (but reversible) forms; 
and v) the creation of special expression vectors and modified E. coli strains (Saida et al. 2006). This 
repressor is also not limited to E. coli, but has also been shown to be effective in other Gram positive 
strains such as Bacillus subtilis where downstream expression efficiencies were similar to those 
reported in E. coli, where only minor codon bias changes needed to be made (Breitling, Sorokin & 
Behnke 1990).   
1.6.3 Visualization of Control: Enhanced Green Fluorescent Protein 
Green fluorescent protein (GFP) has long been used in protein localization because of its ability to 
autocatalytically form a fluorophore without the need for any external agents other than oxygen. Two 
major drawbacks to the use of wild-type GFP are its inability to fold at higher temperatures as well 
as its low intrinsic fluorescence. Due to these drawbacks, mutant versions of GFP have been created 
to improve its use in molecular biology. One such mutant that is commercially available is Enhanced 
GFP (eGFP) (Scholz et al. 2000). It is also worth noting that the properties of GFP can change 
depending on its fusion partner. Aoki et al. (2003) showed through sodium dodecyl sulfate (SDS) gel 
analysis that active and inactive GFPs migrated to different positions. In addition, a single amino 
acid change in the fused polypeptide segment of a GFP-fused polypeptide caused it to migrate 
differently through a urea containing gel (Aoki et al. 2003). GFP has also been successfully 
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integrated into the E. coli chromosome under the control of strong λ PL and PR promoters, regulated 
by cI857; visibly detectable levels of GFP were expressed from the single copy gfp gene as 
temperature was increased (Pinheiro et al. 2008).  
1.6.4 Experimental Rationale 
The goal driving this work was to develop a controllable phage capsid display system that could be 
employed toward biologic-based therapeutics. The scientific basis supporting this study is derived 
from previous findings that the major capsid protein gpD of phage λ tolerates a wide array of fusions 
to its amino and carboxy-termini (Mikawa 1996, Sternberg 1995). A comparison of a traditional wild-
type D protein and a C-terminal D fusion is shown in the schematic below. 
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Figure 3: Schematic diagram of wild-type λ gpD and gpD::X.  
A. Representation of the N and C termini of the wild-type gpD protein. B. Representation of a D fusion protein, 
with a fusion at the C-terminal end. GpD is shown in black, the translational linker in gray and the fusion X 
(eGFP) in white.  
1.6.4.1 Research Objectives 
The objectives defined by this research project included both the bacterial/phage preparative 
component of the work as well as the molecular design and construction.  
1. Identify amber suppression allele effectiveness to suppress the λ Dam15 mutation 
through the assessment of phage viability on different isogenic suppressor strains 
2. Construction of a D::eGFP fusion within the pKS1 plasmid under the control of a 
temperature sensitive CI repressor and test eGFP expression at various temperatures 
3. Measure the ability of pKS1 to complement for the λ Dam15 mutation at various 
temperatures governing D or D::eGFP expression 
4. Introduce both the suppressor and temperature sensitive repressor approaches in a 
single strain and vary both temperature and amber suppressor to determine the 
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number of gpDwt and gpD::eGFP peptides on the capsid surface under each set of 
conditions 
 In order to complete the above objectives studies were performed that combine techniques in 
bacterial genetics, virology and biochemistry. The experiments designed for this research study 
centered on the measurement of suppressor strength and level of plasmid expression. Both qualitative 
and semi-quantitative methods were employed. After the initial sequencing and diagnostic tests, 
isogenic suppressors and eGFP expressing plasmids were created, analyzed individually and then the 
plasmid was transformed into each of the suppressors. From here complementation assays were 
performed using a plasmid expressing wild-type D along with efficiency of plating, qualitative studies 
analyzing both cellular expression and phage decoration with eGFP and finally protein analysis by 
Western blotting was carried out.  
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Media Preparation 
2.1.1.1 LB broth: Used for growing bacterial cultures. 10 g tryptone, 5 g yeast extract, 5 g NaCl/L of 
ddH2O, pH adjusted to 7.8, Antibiotic was added as necessary [Ampicillin, (Ap), 100 µg/mL, 
Tetracycline (Tc), 15 µg/mL] to cooling LB and stored at 4o C. 
2.1.1.2 LB agar: Used for plating bacteria and phage. 10 g tryptone, 5 g yeast extract, 5 g NaCl and 
12 g bacto agar/L of ddH2O. After sterilization, plates were then aseptically poured into sterile Petri 
plates and allowed to cool. Antibiotic was added as necessary (Ap, 100 µg/mL, Tc, 15 µg/mL, Kn, 50 
µg/mL) to cooling agar prior to pouring. 
2.1.1.3 Top agar (used for phage overlays). 10 g tryptone, 5 g yeast extract, 5 g NaCl and 7 g bacto 
agar in 1 L of water. After mixing, media was poured into individual bottles and then sterilized and 
stored at room temperature.  
TN Buffer: Used to dilute cells and phage. 0.1 M NaCl, 0.01 M Tris-HCl at pH 8.0 and sterilized.  
2.1.1.4 Antibiotics: 
Stock ampicillin (Ap) was prepared at a concentration of 100 mg/mL by dissolving the stock powder 
into sterile water and storing at -80° C. Thawed stock solution was then added to sterile media to 
concentration of 100 µg/mL. Tetracycline (Tc) stock was prepared at a concentration of 40 mg/mL by 
dissolving the stock powder into 1:1 H2O: EtOH, filter sterilized and stored at -80° C. Thawed 
antibiotic was then added to final concentration of 40 µg/mL.  
2.1.2 Strain Description  
Summary of strains used and constructed in carrying out this work are shown in Table 1. 
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Table 1: Bacteriophages, Bacterial strains and Plasmids 
Strain Designation Relevant Properties Phenotype Source 
Bacteriophages    
λF7  λDam15imm21cIts D- (Mikawa, Maruyama 
& Brenner 1996) 
λimm21  λ imm21cIts D+ (NBRP-
Prokaryotes(E.coli) 
2009) 
P1rev6 rev6 Super-transducing 
particle 
Gift from B. Funnell 
(University of Toronto) 
P1kc kc  Super-transducing 
particle 
Gift from B. Funnell 
(University of Toronto) 
Bacterial Strains    
BB4 supF58   supE44   HsdR514   galK2   
galT22   trpR55   metB1   tonA   DE(lac)   
U169  
 (Minenkova et al. 
2003) 
W3101 F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1  (Yale University 2011) 
DS-3  F-, phoA4(Am), serU132(AS), his-45, 
rpsL114(strR), valR116 
 (Yale University 2011) 
W3899 F-, glnV44(AS), nadB7  (Yale University 2011) 
K1227 F-, ompF627(T2R), tyrT5888(AS), 
oppC506::Tn10, fadL701(T2R), relA1, 
pitA10, spoT1, rrnB-2, mcrB1, creC510 
 (Yale University 2011) 
CAG 12077   F-, crcA280::Tn10, λ-, rph-1  (Yale University 2011) 
CAG 12156  F-, λ-, uvrC279::Tn10, rph-1  (Yale University 2011) 
W3101 [pKS2] F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1  This study. 
W3101 supD F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
uvrC279::Tn10, serU132(AS),  
 This study. 
W3101 supE F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
crcA280::Tn10, glnV44(AS),  
 This study. 
W3101 supF F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
oppC506::Tn10, tyrT5888(AS) 
 This study. 
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W3101 supD 
[pPL451] 
F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
uvrC279::Tn10, serU132(AS),  
 This study. 
W3101 supE [pPL451] F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
crcA280::Tn10, glnV44(AS),  
 This study. 
W3101 supF [pPL451] F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
oppC506::Tn10, tyrT5888(AS) 
 This study. 
W3101 supD [pKS1] F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
uvrC279::Tn10, serU132(AS),  
 This study. 
W3101 supE [pKS1] F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
crcA280::Tn10, glnV44(AS),  
 This study. 
W3101 supF [pKS1] F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1, 
oppC506::Tn10, tyrT5888(AS) 
 This study. 
Plasmids    
pPL451 PL-cI857-tm  (NBRP-
Prokaryotes(E.coli) 
2009) 
pKS2 (pPL451 gpD) PL-cI857-D  This study. 
pKS1 (pPL451 
gpD::eGFP) 
PL-cI857-D::eGFP  This study. 
Lysogens    
LE392 (Imm21)  (malT   supE44   supF58   hsdR514   




W3899 (λF7)    This study. 
W3101 (λcI857)    (Yale University 2011) 
 
2.1.2.1 Phages Summary 
λF7 (λDam15imm21cIts) is a lambda D amber mutant phage that is unable to grow in the absence of 
an amber suppressor, such a supD, supE, supF. λF7 formed the foundation of this research where 
viability was measured under various conditional scenarios involving suppression, temperature and 
complementation.  
λ imm21 was utilized as a control phage where viability was unchanged regardless of growth 
conditions. This phage is structurally and genetically identical to wild type λ except that the immunity 
region (OLPL-cI857-ORPR) has been recombined with the immunity region of phage 21. This 
heteroimmune phage is thus able to grow on a λ lysogen or any cell expressing the λ cI repressor. 
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P1rev6 and P1kc are high frequency transducing particles that exploit the headful-packaging 
characteristic of P1 phage. P1rev6 and P1kc were used to perform the P1-mediated transductions in 
order to transfer the suppressor alleles into the isogenic background (W3101). P1 has the ability to 
package up to 100 kb or ~2 min of the E. coli genome.  
2.1.2.2 Bacteria Summary 
BB4 (supF58   supE44   HsdR514   galK2   galT22   trpR55   metB1   tonA   DE(lac)   U169 ) served 
as the positive control cell to indicate viability of amber phage (λF7). Viability on BB4 was then used 
as the baseline (denominator) to determine efficiency of plating (eop). BB4 was utilized as 100% 
plating efficiency standard due to the presence of 2 amber suppressors encoded by this strain that 
provide plating efficiencies of λDam15 that were essentially equivalent to that of the wt (λimm21). 
W3101 (F-, galT22, λ-, IN(rrnD-rrnE)1, rph-1) was employed as the nonsuppressor strain and 
negative control for λDam15 plating efficiency. Due to the absence of any amber suppressor (Sup—) 
λDam15 is phenotypically D- on this host and inviable.  
2.1.2.3 Donor Suppressor strains 
DS-3 (F-, phoA4(Am), serU132(AS), his-45, rpsL114(strR), valR116) supplied the supD suppressor 
allele for the isogenic strain. TetR and suppressor alleles were selected within 1 minute of each other 
on the E. coli genome to increase the occurrence of successful transfer of both alleles creating W3101 
supD.  
W3899 (F-, glnV44(AS), nadB7) supplied the supE suppressor allele for the isogenic strain. TetR and 
suppressor alleles were selected within 1 minute of each other on the E. coli genome to increase the 
occurrence of successful transfer of both alleles creating W3101 supE.  
K1227 (F-, ompF627(T2R), tyrT5888(AS), oppC506::Tn10, fadL701(T2R), relA1, pitA10, spoT1, 
rrnB-2, mcrB1, creC510) supplied the supF suppressor allele for the isogenic strain. Strain K1227 
already contains a linked Tn10 allele (TetR ) and therefore only a single transduction was required to 
create W3101 supF.  
Table 4 (below) illustrates the relative genomic address of each suppressor mutation within the E. coli 
genome and the necessary donor strain that supplied the linking TcR gene to permit co-transduction of 
the allele to W3101 background.  
2.1.2.4 CAG Tn10 linker strains 
Two CAG strains were employed to link a TcR marker to each appropriate sup. The strain designation 
and its Tn10 alleles are listed below. The location of the marker relative to the suppressor mutation is 
shown in Table 4. Note in order for the TcR marker to be co-transduced with an allele it must reside 
within 2 min (~100 kb) of the allele to be transferred.  
CAG 12156 (F-, λ-, uvrC279::Tn10, rph-1) allowed for selection of the isogenic supD suppressor 
strain through its linked Tn10 carrying tetracycline resistance.  
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CAG 12077 (F-, crcA280::Tn10, λ-, rph-1) allowed for selection of the isogenic supE suppressor 
strain through its linked Tn10 carrying tetracycline resistance.  
K1227 (F-, ompF627(T2R), tyrT5888(AS), oppC506::Tn10, fadL701(T2R), relA1, pitA10, spoT1, 
rrnB-2, mcrB1, creC510) allowed for selection of the isogenic supF suppressor strain through its 
already linked Tn10 conferring TcR..  
Table 2: E. coli genomic positioning of sup alleles and their associated TcR markers 
Suppressor Mutation Mutation Position 
(min) 
Tn10 Linkage Tn10 
Position 
serU132(AS) (supD) 44.01 uvrC279::Tn10 42.91 
glnV44(AS) (supE) 14.99 crcA280::Tn10 14.14 
tyrT5888(AS) (supF)1 27.74 oppC506::Tn10 28.06 
1 The K1227 strain used for the supF isogenic suppressor contains both the suppressor allele and the TetR marker, therefore only a single 
transduction was required to co-transduce both the marker and linked suppressor from the donor to the nonsuppressor (W3101) recipient. 
2.1.2.5 Isogenic Suppressor Strains 
W3101 supD, supE, and supF derivatives were constructed by co-transducing the AS allele linked to 
the TcR marker from the donor construct into recipient W3101 cells using transducing phage, in doing 
so the genetic background was maintained to ensure that any differences in suppression were entirely 
due to the activity of the AS allele and not strain allogeneity (other potentially confounding mutations 
present within different strain backgrounds). It is however worth noting that the insertion of the Tn10 
marker varies in each strain and as such there is the potential (although highly improbable) that the 
insertion has disrupted a gene that may variably influence the function attributed solely to the 
transduced suppressor mutation. 
2.1.2.6 Plasmids Summary 
1) pUC57-D::eGFP: The translational fusion  (gpD::eGFP 1176 bp) was first synthesized in pUC57 
(2710 bp), which contains a ApR resistance gene and lacZα. In this plasmid D::eGFP was cloned in 
the reverse orientation to  the PLac promoter so the fusion would not be expressed. 
2) pPL451: Plasmid backbone for eGFP expression (gpD::eGFP) and complementation (gpD) 
cassettes. Both cassettes below were cloned into the HpaI and Nco I sites of the multiple cloning 
region.  
 3) pKS1 (pPL451-gpD::eGFP): Plasmid pKS1 was constructed by cutting the gpD::eGFP sequence 
from #1 above and cloning into the HpaI and NcoI sites of pPL451, yielding the finalized pKS1 
plasmid. The resultant sequence creates a C-terminal translational fusion with λF7 gpD (see Figure 3 
below). Removing the terminal stop codon from D and start codon of the eGFP sequence to fuse the 
two genes. The two genes were also separated by an in-frame short linker (T-S-G-S-G-S-G-S-G-S-G-
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S-G-S-G, T = threonine, S = serine, G = glycine) that was placed between and followed by a KpnI cut 
site to maximize fusion functionality and also allow for additional fusions to be designed in the 
future. The gpD::eGFP sequence was then amplified and cloned into the HpaI and NcoI sites on 
pPL451, placing it under the control of a temperature-inducible repressor cI857, conferring 
temperature-regulated expression. 
 
Figure 4: Schematic of pKS1 D::eGFP temperature-regulated fusion expression plasmid  
Schematic of pKS1 expression vector in which the D::eGFP fusion is downstream of the temperature-inducible 
cI857 repressor. gpD and eGFP are separated by a 15 a.a. linker to allow for correct folding of both proteins.  
4) pKS2 (pPL451-gpD): To construct the pPL451 gpD vector, pKS1 was digested by KpnI removing 
eGFP from the C-terminal of the linker to the last 36 C-terminal bp, which was then ligated back 
together to create pKS2.  
 
Figure 5: Schematic of pKS2 pPL451-gpD, complementation plasmid  
Schematic of pKS2 expression vector in which gpD is downstream of the temperature-inducible cI857 
repressor. In addition, a short linker (15 a.a.) separates gpD from the last 36 C-terminal bp of eGFP, which 
include an ochre stop codon.  
2.1.3 Primers 
Primers to sequence the Dam15 mutation of λF7 were designed to base pair on the last nucleotide of 
the amino and carboxyl termini of gene D as follows:   
KS1: Forward D primer:  5ʹ′CACACCAGTGTAAGGGATGTTT -3ʹ′ 
KS2: Reverse D primer:  5ʹ′CCTTTAGTGATGAAGGGTAAAG -3ʹ′ 
Sequencing primers KS1 and KS2 were centrifuged at maximum rpm for 2 min, re-suspended at a 
concentration of 100 mM in sterile molecular grade water and centrifuged for an additional 2 min to 
make stock solutions. 
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2.2 Methods 
2.2.1 Transformation 
Generation of Competent Cells (CaCl2 Method): Cells were grown overnight in 5 mL of LB broth. A 
1/100th dilution was grown at 30°C in LB with vigorous shaking in a large flask to facilitate aeration 
until the cells reached an OD600 between 0.2 and 0.6. Cells were iced for 10 min and then centrifuged 
at 12 K RPM for 5 min at 4° C. The supernatant was discarded and cells were re-suspended in a half 
volume of sterile, ice-cold (4° C) 0.1 M NaCl and left on ice for 1 hour. Cells were then spun down as 
above and re-suspended in a half volume of sterile, ice-cold 50 mM CaCl2 and spun down again. 
Cells were re-suspended in 1/10th volume of CaCl2 and stored on ice. Next a 100 µL aliquot of CaCl2 
competent cells was transferred from pre-frozen stock to pre-chilled 1.5 mL microfuge tubes and 
between 50 and 400 ng of plasmid DNA was added. Tubes were gently mixed and placed on ice for 1 
hour to allow the DNA to adhere to the cells. Then, cells were heat shocked in a 42° C water bath for 
45 to 60 s and immediately returned to ice for 5 min. One mL of LB was added to each tube and tubes 
were incubated at 30° C with gentle shaking for 60-90 min. After incubation, cells were centrifuged at 
12 K RPM for 2 min and re-suspended in 100 µL of fresh LB, and plated on LB + antibiotic plates 
and incubated at 30° C overnight. 
2.2.2 P1 Transduction 
P1 Lysate Preparation: The P1 transduction methodology was adapted from Moore (2011). Briefly, 
20 µL of cells carrying a TcR (Tn10) marker linked to the allele of interest were used to innoculate, 2 
mL LB broth were grown for 30 min at 37° C until the culture was slightly turbid. Next, 20 µL of 
transducing phage lysate grown on a “wild-type” E. coli K-12 (W3101) strain was added. The lysate 
titre of minimum was 5 x 108 pfu/mL concentration. The mixture was grown at 37° C with shaking 
for approximately 2.5 hrs (or until culture is clear from lysis). Tubes were then placed on ice for 10 
min and centrifuged for 15 min at 12K RPM. The supernatant was decanted to a fresh tube and 40 µL 
of CHCl3 was added to sterilize the solution. All lysates were stored at 4° C (Moore 2011). 
 
Generalized Transduction and screening: Freshly grown recipient cells (1.5 mL) were re-suspended 
in 1 mL of fresh 10 mM MgSO4 + 5 mM CaCl2. Next, 100 µL P1 lysate were added to 100 µL of 
recipient cells and the mixture was incubated at 37° C for 20 min. Next, 200 µL of 1 M Na Citrate 
and 1 mL LB was added to each tube. Tubes were then incubated at 37˚ C for 90 min with vigorous 
shaking to allow expression of the relevant antibiotic resistance marker. Cells were then centrifuged 
at 6 K RPM for 3 min and each pellet was re-suspended in 90 µL of LB and 10 µL of Na Citrate and 
the total volume was spread plated on LB plates + antibiotic. Plates were incubated at 37° C for 24 
hrs and colonies were counted and screened as necessary. An LB plate was marked with a grid for 
each cell to be screened. On a second LB plate, loopfuls of λF7 and sterile water were spread (phage 
plate). A sterile loop was touched to the colony to be screened and then the phage plate, and then 
streaked onto the marked LB plate. Plates were incubated for 24 hrs at 37° C and then analyzed for 
plating capability of F7, indicating successful transfer of the sup allele. 
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2.2.3 Construction of Isogenic Suppressor Strains 
Construction of isogenic suppressors was conducted by P1 transduction in two steps: 1) insertion of a 
TcR marker within 100 kb of each AS gene within the donor strain; and 2) co-transduction of both the 
sup mutation and the TcR marker into the recipient (W3101) strain, selecting for Tc resistance. 
Transductants were screened with λF7 for lysis (as above) to confirm the presence of the sup allele.   
2.2.4 Lysate Preparation 
Phage Streaking: 300 µL of indicator cells was added to 3 mL of fresh top agar and the mixture was 
poured evenly onto a fresh LB plate and allowed to set. Next, 10 µL of phage lysate with a titre 
greater than 1 x 108 pfu/mL was transferred onto the plate and was streaked across the plate using 
sterile paper strips isolating for single pfu, using a new piece of paper for each steak. The plate was 
then incubated O/N at the appropriate temperature and single plaques were isolated to generate new 
lysates. 
Primary Culture Lysate Preparation: In a test tube, cofactor (0.01 M MgCl2; and/or 0.01 M CaCl2) 
was added to 300 µL of indicator cells. From a fresh overnight phage streak, a single plaque was 
removed and mixed with cells and incubated for 15-20 min at 37º C without shaking to allow 
adsorption. 10 mL of LB + 0.01 M cofactor was incubated at 37º C in flask before the contents of the 
test tube were added and further incubated for 2.5 – 3 hrs or until lysed (OD600 of 0.05 or less). The 
lysate was then placed on ice for 10 min before being centrifuged for 20 min at 15 K RPM at 4° C. 
The supernatant was decanted and 20-40 µL of CHCl3 was added to sterilize.  
Secondary Lysate Preparation: In a test tube, 300 µl of indicator cells, 10 µL of 1 M cofactor and 10 
µL of prepared (primary) lysate with a titre of >1 x 108 pfu/mL was added and was incubated for 15-
20 min at 37º C without shaking. In a flask 10 mL of LB and 1/100th volume of cofactor was then 
incubated at 37° C with vigorous shaking then mixed with the contents of the test tube and further 
incubated for 2.5 – 3 hrs or until lysed (OD600 of 0.05 or less). Once the solution was clear, the flask 
was placed on ice for 10 min then centrifuged at ~12 K RPM for 20 min at 4° C. The supernatant was 
decanted and 20-40 µL of CHCl3 was added to sterilize.  
Plate Lysate Preparation: Lysate dilution was added to 300 µL of indicator cells + 3 mL of top agar 
and poured onto LB plates and incubated at 37° C for 24 hrs. Plates showing distinct plaque 
formations but mostly lysed were selected for lysate preparation. 10 mL of TN buffer was added to 
the surface of the plate and incubated for an additional 24 hrs at 4° C. The TN buffer was then 
removed and along with underlying top agar and mixed vigorously before centrifuging at 12 K RPM 
at 4° C for 20 min. The supernatant was decanted and 20-40 µL of CHCl3 was added to sterilize. 
Immunity Determination Assay: This was employed to generate a λimm21 lysate to serve as the wild 
type (wt) control for λF7. A λimm21 lysogen, LE392, was centrifuged at maximum speed at 4° C for 
20 min and the supernatant was collected and streaked onto W3101. Two plaques were then placed 
into TN buffer and were used to create a plate lysate. The lysate was titred on W3101 at 1.29 x 109 
pfu/mL. To test phage 21 immunity the lysate was streaked onto a λimm21 lysogen, W3899(λF7) and 
λimm21 lysogen, W3101(λcI857) and observed for plaques. λimm21 yielded lysis on W3101 
(λcI857), but not on W3899(λF7) indicating that the infecting phage carried phage 21 immunity.  
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Lysogenic Inductions: A fresh overnight culture of lysogen was diluted 100 fold in LB + Ap, and 
grown to OD600 = 0.2 - 0.6 at 30° C. The flask was then heated at 65º C for 15 s and quickly 
transferred to 42ºC water bath with aeration until complete lysis was observed (OD600 of 0.05 or less). 
The lysate was then placed on ice for 10 min before being centrifuged for 20 min at 15 K RPM. The 
supernatant was decanted and 20-40 µL of CHCl3 was added to kill any remaining cells. 
Phage titering: A 1/100 serial dilution series was prepared in TN buffer. Next 100 µL of lysate 
dilution was added to 300 µL of indicator cells + 3 mL of top agar and poured onto LB plates and 
incubated between 30 and 40° C for 24 hrs. Plaques were counted and plaque number was then 
multiplied by the dilution factor to determine the lysate pfu (plaque forming unit) titre (pfu/mL).  
2.2.5 Phage Filtering and Concentration 
Primary lysates (10-20 mL) were clarified of any cell debris (as above) then further filter purified by 
passaging through a 0.4-micron filter. In some cases, lysates were further purified by adding lysate to 
an Amicon Ultra-15 Centrifugal Filter, then centrifuged at 5 K x g at 4° C for 15-30 min. After 
centrifugation the filtrate was removed. Protein concentration (Protein at A280) was then determined 
by Nanodrop 2000 (Bio-Rad, Mississauga ON). Filtration was performed to both purify and 
concentrate whole phage lysates and remove any potential free gpD::eGFP monomer in preparation 
for protein analysis.  
2.2.6 Functional Immunity Marker Rescue Assay 
Three hundred microlitres of homoimmune lysogen and 10 µL of lysate was added to 300 µL of 
indicator cells + 3 mL of top agar and poured onto LB plates (with or without antibiotic) and 
incubated at 30° C for 24 hrs. Next, a toothpick was used to capture a small amount of donor lysogen, 
which was then stabbed into phage cell mix overlay. Plates were incubated at 30° C for 24 hrs and 
observed for lysis spot formation. Any lysis that developed was due to the presence of homologous 
recombination between the donor lysogen and the recipient phage replacing the deficient allele 
(marker rescue) or the immunity region (FI Assay) and these were picked with a Pasteur pipette and 
stored in TN buffer for further screening.  
2.2.7 Semi-quantitative phage titration 
An indicator cell overlay was prepared on agar plates as described above. A matrix was drawn on the 
plate to indicate an array of phage at an incremental dilution series (10-1 – 10-4) of each phage, 
prepared in TN buffer. Next 10 µL of each phage dilution was transferred with a pipette to the spot on 
the corresponding matrix and the plate was incubated at 30° C for 24 hrs. After incubation, the plate 
was examined for the presence/absence of plaques and relative extent of lysis. In the cases where 
individual plaques were visible within the lysis spot, plaques were counted and titer was determined. 
This assay was used to determine best dilutions to carry out full plate titration assays. 
2.2.8 Cell Viability (Titration) Assay 
Overnight cultures of cells were grown at 30° C and diluted 100 fold in fresh 10 mL of LB broth and 
grown at 25° C until OD575 = 0.4 - 0.5. A dilution series was prepared in TN buffer and each cell was 
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plated on both LB + antibiotic plates when pertinent. Plates were incubated overnight at 30°, 32°, 35° 
and 37° C. Colonies were then counted and multiplied by the dilution factor to determine the cell titer 
at that temperature (cfu/mL) and divided by the total number of cells initially present to determine the 
relative viability. 
2.2.9 Complementation Assays 
Full genomic length phage λF7, carrying the Dam15 mutation, is incapable of packaging on a 
nonsuppressor host W3101, but the mutation is suppressed on strain BB4 that possesses two AS 
mutations (SupE, SupF). λF7 grows equally effectively as its D+ counterpart on this strain, and is 
conventionally considered to confer “100%” relative efficiency of plating (eop = 1). λF7 was plated at 
varying dilutions on strains at 30, 32, 35, 37, or 39° C and eop was scored against BB4 to determine 
relative plating efficiency of the tested phage. Relative plating efficiencies were then divided by that 
on BB4 (100%) to derive the eop. Relative eop was determined as a ratio of λF7 eop divided by 
λimm21 eop at each tested temperature. This strategy was employed to derive an eop for the 
experimental phage preparations that is independent of plating differences of λ due to temperature or 
other confounding variables.  
2.2.10 Fluorescence (eGFP) Assays 
Overnight cultures of cells were grown in LB + antibiotic at 30° C. Cultures were diluted 10 fold in 
fresh LB + Ap and grown for 24 hrs at experimental temperatures before measuring A575. Each cell 
sample was then diluted to a titre of 1 x 109 cfu/mL in TN buffer and 1 mL was transferred to a 24-
well cell culture plate and observed under GFP filter (Excitation = 470 nm, Emission = 535 nm).  
Qualitative Fluorescence analysis of host cells: Overnight cultures were grown in LB + Ap at 30° C 
then diluted and grown at varying experimental temperatures. Each cell sample was then diluted to a 
titre of 1 x 107 cfu/mL in TN buffer and 1mL was transferred to a 24-well cell culture plate and 
observed under an eGFP filter (Excitation = 470 nm, Emission = 535 nm). Background fluorescence 
was corrected against an eGFP— control strain.  
Qualitative Fluorescence analysis of EGFP-decorated phage: Lysates were diluted to a titre ranging 
between 1 x 103 - 1 x 108 pfu/mL in TN buffer and 1 mL was transferred to a 24-well cell culture 
plate and observed under a GFP-specific filter (Excitation = 470 nm, Emission = 535 nm). 
Background fluorescence was corrected against an eGFP— control strain.  
2.2.11 Immunoblotting 
Immunoblot experiments were conducted using rabbit anti-gfp polyclonal antibody (gift of Dr. B. 
Moffatt, University of Waterloo). Samples were mixed with loading dye and denatured by boiling for 
10 min, and placed on ice and centrifuged. A total volume of 20 µL was electrophoresed with a range 
of 100-200 ng of total protein in each. Samples were run along side a GFP standard ranging from 10 
pg/µL to 100 ng/µL as positive standard then separated by 15% SDS-PAGE. After electrophoresis the 
gel was placed in transfer buffer (48 mM Tris, 39 mM glycine, 20% (v/v) methanol, 0.0357% (w/v) 
SDS, pH 9 to 9.4) for 10 min. The protein was transferred to a nitrocellulose membrane at 20 V for 45 
min using a Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad, Mississauga ON). The membrane 
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was then stained with Ponceau S stain (0,2% w/v) by shaking for 10 min and de-staining in dH2O 
until bands were visible. The stain was then removed by shaking in 1X PBS buffer until the stain (and 
bands were no longer visible). The membrane was then placed in PVA for 30 s to block, and then 
washed in PBS/milk/Tween for 10 min. The membrane was then incubated at 4° C overnight in 
PBS/milk/Tween plus 1/30th dilution of primary rabbit anti-GFP antibody. After incubation the 
membrane was washed three times for 10 min in PBS/milk/Tween and then the secondary AP 
conjugate antibody (anti-rabbit) was added at a 1:2000 and incubated for two hrs, rinsed three more 
times with PBS/milk/Tween for 10 min then a final rinse in PBS was performed for five min. To 
detect bound antibody the membrane was placed in a pool of ECF and then visualized with a 
Typhoon imaging system. A second membrane was blocked with TBST for one hour at room 
temperature and incubated with primary antibody (1:30) for one hour at room temperature and 
washed three times for 10 min with TBST and then incubated with a different secondary antibody 
(gift from Dr. Michael Beazely, University of Waterloo) in TBST for one hour at room temperature 
and then washed again three times and the bands were detected with SuperSignal West Pico 
Chemiluminescent substrate and visualized on a Kodak imaging system.  
2.2.12 Sequencing (λDam15) 
A 10 mM dilution of the KS1 forward and KS2 reverse sequencing primers (Sigma-Aldrich, USA) 
were prepared in sterile molecular grade water and used to PCR amplify the Dam15 allele. A standard 
gradient PCR was performed using Phusion high fidelity DNA polymerase to determine the optimal 
Tm (65, 61.4, 57, and 55° C) for the primers. A standard three-step PCR cycle was then performed at 
optimal Tm (61.4° C) to amplify the gpD sequence. λF7 phage lysate was used as the template for all 
PCR cycles. PCR products were then purified from a 0.8% agarose gel via QIAquick Gel Extraction 
kit (Qiagen, Toronto ON) and sent to University of Waterloo, Department of Biology Core Facility as 
well as the York University Automated DNA Sequencing Facility for sequencing. Cycle sequencing 
reactions were done with BigDye Terminator on the Applied Biosystems 3130xL DNA Sequencer. 
2.2.13 DNA Manipulation 
Plasmid Extraction and Purification: Purification of plasmids was conducted using Promega Wizard 
Plus SV Miniprep DNA Purification System (Promega, Madison WI), described here in brief. Cells 
(1.5 mL) were pelleted (all centrifugation steps were performed at ~12K RPM) for 10 min then re-
suspended in 250 µL of re-suspension solution. Next, 250 µL of lysis solution was added and the tube 
was inverted 4 times to mix. Next, 10 µL of alkaline protease solution was added and the tube was 
once again inverted to mix and incubated for 5 min. Finally, 350 µL of Neutralization Solution was 
added and the tubes were inverted to mix, then centrifuged for 10 min at room temperature. A spin 
column was inserted into a collection tube and the cleared lysate was decanted into the spin column, 
and then centrifuged for 1 min. To wash 750 µL of wash solution was added and the tube was 
centrifuged for 1 min. A second wash was performed using 250 µL of wash solution and then a final 
centrifugation step was performed for 2 min to remove any excess wash. The DNA was then eluted 
by adding 40 µL of sterile molecular grade water to the column and centrifuging for 1 min into a 
sterile 1.5 mL microfuge tube and then adding an additional 40 µL of water and performing a second 
spin into the same tube.  
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Gel Extraction of DNA Fragments: DNA fragments were extracted via QiaQick Gel Extraction Kit 
(Qiagen, Toronto ON). Briefly, the DNA fragment was excised from the agarose gel and dissolved in 
Buffer QG at 50° C. Next the mix was spun through a QIAquick spin column and 0.5 mL of Buffer 
QG was again added and spun through the column to remove any residual agarose. The filter was 
then washed with 0.75 mL of Buffer PE and centrifuged for an additional 1 min to remove all wash, 
before the column was placed into a clean 1.5 mL microcentrifuge tube and DNA eluted by spinning 
40 µL of sterile molecular grade water through the column.  
DNA ligation: NEB Quick Ligation kit (New England Biolabs, Whitby ON) was used for all 
ligations. A minimum of 50 ng of vector DNA was combined with a 3-fold molar excess of insert. To 
this mixture a 10 µL of 2X Quick Ligation Buffer and 1 µL of Quick T4 DNA Ligase was added and 
the solution and the volume was adjusted with ddH2O to a final volume of 20 uL and mixed. The 
tube was then incubated at room temperature (25° C) for at least 2 hrs before it was used to transform 
JM109 or DH5α cells.  
Quality Assurance: To ensure that the plasmid construct was correct, a simple nucleic acid digestion 
was performed. The pPL451 plasmid was digested by HpaI and pPL451 gpD::eGFP and pPL451 
gpD were double digested by HpaI and NcoI. For all digestions approximately 500 ng of DNA was 
digested and visualized.   
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Chapter 3 Results and Discussion 
3.1 Strain and Construct Selection and Characterization 
3.1.1 Sequencing of λDam15  
The bacteriophage utilized as the carrier in all phage display experiments was λ F7 (λimm21Dam15). 
This phage possesses two important differences versus wild type λ: 1) it possesses the immunity 
region of phage 21, and as a heteroimmune phage it is not sensitive to the λ cI repressor and is 
therefore capable of growth on a λ lysogen, or cell expressing cI repressor; 2) the λF7 phage carries 
an amber mutation in the major capsid gene D that is necessary to compact full-length λ genome into 
the capsid and provide structural integrity. The phage is unable to grow on a wild-type E. coli K-12 
strain, can make plaques on particular amber suppressor mutant strains. 
I first sought to determine the exact location of the point mutation in the λDam15 allele by 
DNA sequencing of the PCR amplified sequence. The derived sequence was then compared to wild-
type gpD (Accession number NC_001416.1). The amplified 333 bp Dam15 gene is shown in Figure 
6. The amber mutation was localized to the 204th bp of D, converting the 68th CAG (glutamine) 
codon, to an amber stop (TAG) codon. In a nonsuppressor cell the presence of the amber mutation 
will be read as a stop codon and result in a truncated and non-functional gpD that is essential to 
package strains full length λ DNA and hence phage viability. Growth of Dam15 phage on various 
suppressors will result in the substitution of a amber stop codon for an amino acid. While only SupE 
strains will insert glutamine at the 68th codon restoring the native sequence, SupD will substitute a 
serine residue to produce a gpDQ68S allele and SupF will substitute tyrosine to produce a gpDQ68Y 
allele. The efficiency of plating data below agrees with historical literature, which found that the supE 
suppressor, encoding glutamine in place of the amber codon (restoring the native sequence) was the 
most effective in restoring viability of λF7 (Mikawa, Maruyama & Brenner 1996).  
 














Figure 6: Sequencing of λDam15 
A: 1kb and 100 bp DNA ladder reference chart (New England Biolabs). B: Lane 1: 1 kb ladder; Lane 2: 100 bp 
ladder; Lane 3-4: Amplified 333 bp Dam15 allele from λF7*; Lane 5: non-functional PCR product; Lane 6 PCR 
negative control.  
3.1.2 Genetic Screening of Phage and Bacterial Candidates 
As many of the phage and bacterial strains that were utilized in this work were acquired from other 
labs, making it essential to first perform appropriate diagnostics on these strains to ensure that their 
phenotype agreed with their documented genotype. Each phage was diluted and three different 
concentrations were plated on four well known experimental bacterial strains of E. coli K-12. Lysis 
(amount of clearing) was scored on each strain qualitatively as either no detectable lysis (-), evidence 
of lysis (+) minor lysis (++) or full lysis (+++). The results shown in Table 5 indicate that both λF7 
and λcI857 were unable to grow on their respective lysogens (λimm21 and λ, respectively) as 
expected due to homoimmunity. λF7 was also unable to grow on the Sup— (W3101) strain, due to the 
inability of this wild-type strain to suppress the Dam15 mutation. As expected, λimm21 (D+) that has 
no packaging constraints, showed consistent growth across all strains. Finally, both λF7 and λimm21 
demonstrated equivalent unimpeded growth on the double suppressor strain, BB4 (supF58 supE44). 
The confirmation of these phenotypic characteristics was essential to ensure that all work was done 
with the proper genotypes taken from a variety of different sources (see Table 3) and that downstream 
experiments could be performed with confidence.   
* 
   1        2        3        4        5       6 
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Table 3: Genetic Testing of Bacterial and Phage Strains 
 Nonsuppressor3 Suppressor3 W3101 (λcI857)4 W3899 (λF7)4 
Phage 
Conc. 
10-9 10-7 10-5 10-9 10-7 10-5 10-9 10-7 10-5 10-9 10-7 10-5 
λD-2 - - - - ++ +++ - - ++ - -  - 
λD+12 ++ +++ +++ ++ +++ +++ ++ +++ +++ ++ +++ +++ 
λD+22 - ++ +++ - ++ +++ - - - - ++  +++ 
1- = no detectable lysis, ++ = slight lysis, +++ = Full lysis 
2 λD- = F7,λD+1 = Imm21, λD+2 = cI857 
3 Nonsuppressor = W3101, Suppressor = BB4 
4 W3101 (λcI857) and W3899 (λF7) are both lysogens 
3.1.3 Characterizing λF7 
In order to further characterize λF7 it was necessary to determine optimal growth temperature and 
reversion frequency. To ascertain optimal growth temperature, λF7 was grown on a double 
suppressor (BB4) at various temperatures. Reversion frequency was established by growing λF7 on a 
nonsuppressor strain (W3101) at various concentrations and then examining plates for the presence of 
plaques.  
3.1.3.1 Effect of Temperature on λF7 Viability 
Coliphage grow best at mammalian body temperatures between 37-39o C. Not surprisingly, a slight 
change in λ (D+) and λ (D-) titres at various temperatures was observed on the respective permissive 
hosts (Sup+). λDam15 is non-viable on the Sup— strain regardless of the temperature at which the 
strain is grown, and therefore this data was omitted. Table 4 summarizes the data of the titres 
observed at 30° C, 37° C and 42° C for the λ D+ and D- derivatives. The table values are expressed as 
the efficiency of plating (eop) with the optimal growth temperature of 37o C set to one, to show the 
subtle differences in phage viability at temperatures above and below optimal temperature.   
Table 4: Effect of Temperature on λF7 Viability 
Temperature (°C)  λD- Titre 1,2 λD+ Titre 1,2 
30°  C 0.52 0.55 
37°  C  1.00 1.00 
42°  C 0.19 0.96 
1 Titres are eops based on use of BB4 as 100% plating efficiency 
2 λD- = F7, λD+ = cI857 
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3.1.3.2 Calculating λF7 Reversion Frequency on Sup— Strain 
As a general rule, it can be expected that revertants to point mutations occur at a frequency of ~10-6. 
To determine the best concentration to plate λF7 on the Sup— strain (W3101), in the absence of 
revertants, λF7 was plated at various concentrations. Concentrations where no plaque formation was 
observed are indicated by n/a in Table 5.   
Table 5: λF7 Titre on sup- strain (W3101) and various concentrations 





1Indicates the absence of plaques being observed on agar plates at the specified phage concentration. 
3.1.4 Isogenic Suppressor Construction 
The ability of a mutant strain to suppress a conditional amber mutation is conferred by a second site 
mutation in a tRNA gene that is capable of reading a UAG stop codon and inserting an amino acid in 
its place. To ensure isogenicity and that suppression of the amber mutation was entirely conferred by 
the amber suppressor, a series of amber suppressor genes were transduced into the nonsuppressor, 
W3101 background. Suppressor alleles were transferred from donor strains by linking each to a Tn10 
TcR marker. A two-step transduction process transferred genes, whereby a marker was first linked to 
the suppressor allele, then the suppressor allele plus TcR marker was transferred to the recipient 
nonsuppressor strain. Table 6 displays the expected gene linkages for each of the suppressor strains 
and the observed linkages that were seen during the transduction process. While supE and supD 
transfers agreed reasonably with expected linkages, supF linkage of fadR613::Tn10 to the tyr58 allele 
was observed to be farther apart than expected (<10% vs 43% expected). This difference could be 
attributable to an unrecorded insertion between the two genes in supF donor strain, or more likely, 
due to the limited number of transductants obtained (8) by which to score percent linkage. Indicated 
in the table are also the locations of both the suppressor mutation and the Tn10 marker. These 
locations were critical in the initial design of marker linkages due to the limited packaging 
capabilities of the general transducing phage P1 at ~100 kb or approximately two min of the E. coli 
genome. Linkage further than this distance exceeds the length of packaging capabilities of P1 and 
would render co-transduction of the marker and the allele in tandem unattainable. In order to screen to 
ensure that the sup+ allele was co-transduced with the TcR linkage marker, λF7 was plated on all TcR 
candidate strains, to determine whether it was capable of growth on the transductant. If the suppressor 
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SupE (glnV44) 14.99 crcA280::Tn10 14.14 57.5% 50% 0.85 
SupF (tyr58)3 27.74 fadR613::Tn10 28.06 43.0% <10% 0.32 
SupD (serU132) 44.01 uvrC279::Tn10 
 
42.91 45.0% 37.5% 1.1 
1 Two different phages were used in the transduction experiments. The first was p1kc (Titer = 1.34 x 109) and the second was p1rev6 (Titer 
= 1.10 x109) 
2 # of transductants ranged from 8 to 200 
3 The supF strain that was employed in the final transduction already contained a TetR linked gene and therefore only one transduction was 
required to transfer both genes 
3.1.5 Efficiency of Plating of λDam15 on Isogenic Suppressor Derivatives (37° C) 
To determine the eop of the isogenic suppressor strains at 37° C, λF7 was plated on each. The eop 
was then determined by dividing by the titre on each strain by that obtained on BB4 and then by the 
eop yielded by the D+ phage control, λimm21. The results are shown in Table 7. Overall, the presence 
of a suppressor does not appear to restore a significant level of viability (results are the percentage 
efficiency as compared to the positive control phage λimm21). This will be an important finding to 
compare when looking at the efficiency of plasmid-mediated complementation below.  
Table 7: Efficiency of Plating of λDam15 on Isogenic Suppressor Derivatives (37°C) 
Bacterial Host Cell1 Efficiency of plating (eop)2 
W3101 1.92 x 10-6 
W3101 supD <1.13 x 10-5 
W3101 supE 0.09 
W3101 supF 0.19 
1 N =3, each strain was plated for 3 separate trials 
2 eop’s were scored using BB4 as the 100% plating efficiency standard 
3.1.6 Discussion 
The ability of gpD to accept fusions of large peptides and proteins and lambda’s high infectivity has 
given λ an advantage over the traditional use of filamentous phage for display. Assembly of the λ 
capsid is accomplished in two steps: 1) prohead assembly; and 2) DNA packaging. During DNA 
packaging there is a large scale, irreversible, conformational change of the prohead, where there is an 
increase in volume and stability. During packaging, when only gpE is present, the capsid shape is 
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transformed from being more rounded to its final icosahedral structure with the subsequent binding of 
gpD to each face. The gpD protein is described as “thimble-shaped” with protrusions that are 
arranged in trimers once bound to the prohead. The trimer itself is shaped as a hollow triangle with 
rounded sides where the “bottom side” binds to the capsid. The “top” ends are relatively hydrophilic 
and exhibit both positive and negative charges, while the “bottom” is hydrophobic. The N-terminus 
likely governs interactions with gpE as it is situated near the interface. This conclusion is supported 
by the fact that if the N termini of gpD is truncated no viable progeny are produced. Furthermore, 
since the N-terminus sits at the interface of gpE/gpD, and the fact it still accepts fusions, suggests that 
it either underlies the trimer, connecting it to the capsid, remaining exposed to accept fusions, or it is 
threaded across the interface so it can still display fusions on the outside. The gpE and gpD proteins 
interact at three-fold sites of the capsid surface lattice forming twenty icosahedral facets in total 
(Yang et al. 2000, Sternberg, Hoess 1995, Mikawa, Maruyama & Brenner 1996).  
 It is important to understand the structure and function of gpD when assessing its ability to 
act as an appropriate fusion partner and determining whether to exploit an N or C terminal fusion. 
The gpD protein is thought to be a good fusion partner for several reasons. First, it does not contain 
any cysteine residues, which eliminates the misplacement of disulfide bonds under oxidative 
conditions, which may lead to misfolding and aggregation with the fusion partner. Secondly, gpD 
lacks enzymatic activity, which is important when discussing fusions, where in eukaryotic cells, 
activity may interfere with cellular signal transduction. The gpD protein is also stable at elevated 
temperatures for long periods of time and can remain soluble for prolonged periods of time at these 
increased temperatures (Forrer, Jaussi 1998). It is characteristics like those above coupled with a long 
history of phage display that has made gpD an ideal candidate to employ as a fusion partner 
throughout the remainder of this study.  
Upon sequencing the Dam15 allele of λF7, the location of the amber stop mutation was 
localized to the 68th residue of the gpD 110 a.a. protein. The presence of this stop codon also indicates 
the truncation size of gpD when λF7 is grown on a nonsuppressor strain of E. coli, which renders the 
phage non-viable. In determining the sequence of the stop codon, I concluded that the SupE strain 
would restore the sequence and hence, would be expected to be the most efficient at suppressing the 
Dam15 mutation. This finding agrees with previous findings of Mikawa et al. (1996) who observed 
that a SupE strain (TG1) showed the strongest suppression activity of the Dam15 mutation.  
All phage strains tested were unable to grow on their respective lysogens (λF7, λcI857, and 
λimm21) as expected, ensuring heteroimmunity between λ and λF7 (λimm21Dam15) phages and that 
λimm21 and λF7 were indeed homoimmune. Despite the expectation that λF7 would be unable to 
grow on the nonsuppressor (W3101) strain, the confirmation of this phenotype was also critical to the 
downstream applications. Many wild-type strains vary in their ability to impart a Sup— phenotype and 
identifying a Sup— host that strongly inhibits λDam15 phage propagation was paramount to 
developing Sup+ derivatives. The phage D+ counterpart to λF7, λimm21, showed consistent growth 
across all strains, confirming that no other factors were modulating λF7 efficiency of plating. λF7 and 
λimm21 also both grew equally well on the double suppressor strain, BB4 (supF58   supE44); an 
important finding as this strain was to serve as the positive bacterial control in forthcoming 
experiments and as the 100% efficiency of plating (eop) marker in subsequent relative eop plating 
experiments.   
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λF7 (D-) had the highest titrre when grown on a suppressor strain at 37° C. The reduced eops 
at lower temperatures could be attributed to poorer adsorption and infection efficiency of this phage 
that thrives in the natural environment of 37-40o C or they could also be caused by temperature-
related changes to E. coli receptor expression producing suboptimal phage binding. The exponentially 
lower (<10-4) eop of λF7 on the Sup— host (W3101) is due to the inability of this strain to confer 
suppression of the amber mutation within the essential late structural capsid gene D, resulting in a 
truncated and nonfunctional gpD product, yielding non-viable phage. Any plaques seen here can be 
attributed to intragenic reversion mutations that restore gpD functionality, expected at ~10-6 
frequency. 
A general transduction strategy was employed to construct an isogenic suppressor set, 
eliminating any additional mutations that may have confounded growth and viability results between 
allogenic sup+ donor strains. Each transduction was successful but, in the case of supF, the observed 
linkage was found to be considerably lower than the expected gene linkage to the TcR marker. While 
there is a possibility that the donor strain has experienced an insertion between the two linked genes, 
dropping the co-transduction frequency, it is more likely that the observed linkage was due to the 
relatively low number of transductants that was isolated. A very low number of transductants were 
also observed for supE, which may be justified by the fact that the suppressor gene is situated very 
close to the integration site of λ, attB, which has been documented to make transduction of this gene 
particularly difficult in the case that the donor strain is a λ lysogen, which may induce the phage upon 
transduction to the recipient (Inokuchi et al. 1979).  
Interestingly, λF7 formed very small plaques on W3101 supD compared to D+ λimm21 
plaques on the same cells. Viability of λF7 was also very poor on this suppressor and much closer to 
that of the Sup— strain than it is to the other two suppressor siblings. This indicates that W3101 supD 
is a very poor suppressor and much of the gpD Q68S protein that is produced is either poorly 
integrated into the gpD translated product, or the Q68S protein possesses very poor gpD functionality. 
This may be attributed to the fact that the inserted serine in the place of a glutamine, which is a much 
larger and polar amino acid, does not possess the necessary size or chemical attributes to properly 
substitute for glutamine. This poor substitution for gpD function is a welcomed addition to the sup 
group as it provides an important dimension to the project in balancing nonfusion gpD allele 
incorporation vs gpD::eGFP inclusion; allowing more fusions to be incorporated per phage capsid 
than the stronger suppressors. In contrast, both supE and supF show much higher levels of 
suppression and therefore phage viability, with supF performing slightly better than that of supE, 
which was surprising in that it would be expected that the most effective suppressor would be that 
that restores the native codon (Mikawa, Maruyama & Brenner 1996, Normanly et al. 1986). 
3.2 Construction of temperature-regulated D and D::eGFP expression 
plasmids  
3.2.1 Construction and Characterization of the pKS Plasmid series 
The pKS1 plasmid, placing the D::egfp under temperature-sensitive repressor (cI857) control of the 
strong λ PL promoter, was manipulated to create pKS2 by removing the egfp gene. The final plasmid 
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contains the wild-type λD gene in addition to the final 36 bp from the 3ʹ′ end of the eGFP gene. A 
KpnI digest was used to remove the eGFP gene leaving the beginning of the linker that sits just 
downstream of gpD until the KpnI site found at the 3ʹ′ end of the eGFP gene. Figure 7 shows a 
schematic of the eGFP removal from pKS1, leaving the D gene with the linker. The downstream 
region of the D gene after being cut with KpnI was sequenced as 5ʹ′-
GGTACCGCGGGCCCGGGATCCACCGGATCTAGATAA-3ʹ′, this sequence concludes with an ochre 












Figure 7: Construction of the pKS2 gpD plasmid 
Schematic representation of the construction of pKS2, blue is the gpD gene, red is the linker, and green is the 
eGFP gene. The initial fragment was 1176 bp, which comprises gpD::linker::eGFP. After digestion by KpnI the 
final fragment was 410 bp and was comprised of the gpD gene and 36 bp of the 3ʹ′ end of the eGFP gene. The 
downstream eGFP bp additions are 5ʹ′-GGTACCGCGGGCCCGGGATCCACCGGATCTAGATAA-3ʹ′, with 
the stop codon being TAA (ochre). The KpnI site is underlined in the sequence above.  
3.2.2 pKS1 Transformation Verification 
To confirm that the transformed plasmid carried the correct sequence plasmid DNA a simple nucleic 






















	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  












Figure 8: pKS1 Transformation Confirmation by Digestion 
A: 1 kb and 100 bp DNA ladder reference (NEB). B: Plasmids extracted from the suppressor cells were 
digested to yield the presence of D::eGFP or D. Lane 1 and 2 are a 1 kb and 100 bp DNA ladder respectively;  
Lanes 3, 5 and 7 are uncut pPL451, pKS1 and pKS2, respectively. Lane 4: pPL451 digested with HpaI; Lane 6 
and 8: pKS1 and pKS2 double digested by HpaI and NcoI. In Lane 6 and 8, D::eGFP and D can be observed at 
approximately 1176 and 410 bp, respectively. For all digestions 500 ng of DNA was analyzed in each case. 
3.2.3 Analysis of gpD Complementation 
To determine the level of gene D expression under various temperature conditions, the nonsuppressor 
strain W3101 was transformed with the pKS2 plasmid. Since gpD is an essential protein to package 
full length λ genomes, the ability to properly package and produce viable particles relies upon in trans 
complementation for the phage-borne Dam15 mutation by the gpD fusion proteins expressed from 
pKS2. As expected, at increasing temperatures, complementation for Dam15 by plasmid-encoded D 
increased, with optimal results seen at 37o C. Complementation results for each temperature tested are 
presented in Table 8. Relative eop was determined based on plating results on the double suppressor 
(BB4) at the same temperature.  
Table 8: Complementation of the λ Dam15 mutation in trans via expression of D from pKS2 
Temperature (°C) Efficiency of Plating (eop)1 
32° C 5.10 x 10-4 
35° C 5.60 x 10-4 
37° C 1.02 
39° C 1.02 
1 averaged data from 3 separate trials 
2 eop was either identical or higher than that achieved on the double suppressor strain BB4  
gpD::eGFP (1176 bp) 
gpD:: (410 bp) 
pPL451 backbone 
    
   1      2     3    4     5     6    7     8 
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3.2.4 Assaying toxicity of D::EGFP expression in host cells 
It was important to ensure that plating efficiencies of λDam15 phage on cells harbouring the pKS1 
plasmid were not confounded by potential toxic effects of pKS1-mediated D::gfp over-expression 
within the nonsuppressor strain, W3101. To test this, the efficiency of plating of W3101 carrying the 
plasmid backbone was grown at a variety of temperatures and compared to the same strain carrying 
pKS1. To examine the plasmid expression toxicity, pKS1 and pPL451 transformants were assayed for 
viability at various temperatures. Cells were plated on both LB and LB + antibiotic plates and the 
relative cell viability eop was determined by dividing the pKS1 cell titre by the backbone titre. 
Results indicated little difference in eop between antibiotic and non-antibiotic scenarios at all 
temperatures tested (Table 9). Interestingly, larger colonies were observed at temperatures of 35° C 
and above, but no remarkable toxic effect of the D::egfp fusion expression was observed.  
Table 9: eGFP Expression Effect on Cell Viability 
Temperature W3101 [pKS1]3 Efficiency of 
Plating (eop) 
W3101 [pKS1]3 eop 
RT (22-25°  C) 1.83 x 108 11 2.20 x 108 0.78 
30°  C 1.33 x 108 0.67 2.64 x 108 0.84 
32°  C 2.22 x 108 11 2.60 x 108 0.88 
35°  C2 1.01 x 108 060 2.54 x 108 0.89 
37°  C 1.45 x 108 0.65 2.31 x 108 0.90 
1eop slightly greater than 1.  
2 Larger colonies were observed at temperatures of 35° C and above  
3 Column 2 was plated on LB + Ampiciilin and the Column 4 were plated on LB 
3.2.5 Fluorescence Assays 
3.2.5.1 Determination of cellular expression of eGFP 
Plasmid pKS1 was constructed in order to provide varying levels of eGFP expression, controlled by a 
temperature-sensitive λ cI857 repressor during infection by λF7. To better observe the activity of 
pKS1 under various temperatures, imaging was performed using a Kodak imaging system with the 
appropriate GFP filters. Cellular cultures of W3101 (pKS1) and W3101 (pKS2) were titred to 1 x 109 
pfu/mL after which the qualitative level of eGFP expression was observed by placing 1mL of lysate 
into a cell culture plate and then viewing the fluorescence on a gel doc equipped with a GFP filter. 
Since all cultures are derivatives of W3101, the original strain was used to demonstrate basal 
expression (Figure 9). 
 
 






Figure 9: Cellular expression of eGFP (25-37°C) 
A: Relative cellular eGFP protein expression at 25, 30 and 37° C (left to right). Experimental 
W3101 [pKS1] (top), and control W3101 [pKS2] (bottom) to adjust for background signal. B: 
Relative cellular eGFP protein expression at 32, 35 and 37° C (left to right). Bacterial cells as 
above. W3101 was used as the cell control and TN buffer was also included to ensure that 
media alone did not produce a signal. TN buffer was placed in a single well and used as an 
overall control since lysates were diluted in TN, yielding no fluorescence. Initially three 
temperatures were selected based on the theoretical dissociation temperature of the cI857 
repressor (A). When fluorescence was only observed at 37° C and no gradual signal was 
detected, activity was reconfirmed with a second experiment utilizing a more sensitive 
temperature range to determine if a more precise level of expression could be observed when 
smaller increases in temperature were used to detect eGFP expression (B).  
25     30      37 
32     35      37 
 white light  fluorescence 
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3.2.6 Discussion 
It was important to determine whether in the absence of a suppressor, a plasmid-mediated approach 
could supply enough gpD to generate not only viable but also fluorescent phage. As expected, the 
eops for phage complemented with pKS1 (D::eGFP) were lower than that of pKS2 (D) likely due to 
the hindrance to folding imposed by the fusion to eGFP.  
After plasmid construction (pKS2) and confirmatio, it was important to ensure that the level 
of expression was under control of the cI857 repressor as expected.. As the temperature increases the 
repressor becomes more labile and there should be an increase in gpD transcription and therefore 
increased levels of gpD produced and incorporated into assembling phage; optimal incorporation is 
expected at 37° C.  
 As shown in Table 8, there is a significant difference in the degree of complementation at 35° 
C versus 37° C. This finding is not surprising as the λ repressor retains considerable functionality at 
35o C, but drops to 1% at 37o C. Not only did complementation increase as temperature increased, as 
expected, but in addition, the eop at both 37 and 39° C was 100% of that compared to λDam15 grown 
on the double suppressor BB4, indicating that full functionality can be restored via plasmid-mediated 
in trans complementation in the absence of any suppression. Zanghi et al. (2005) performed a 
plasmid-mediated in trans complementation for gpD into a D-deficient λ and showed that when D 
was expressed, phage readily grew.  
 Previously, Sternberg and Hoess (1995) showed that recombinant gpD protein could be added 
to the phage capsid in vitro and incorporated into phage using in trans complementation. This study 
also showed that fusion proteins could not occupy all gpD sites on the capsid as phage were still 
sensitive to EDTA, which indicates the occurrence of empty gpD sites. When phage lack gpD are 
exposed to EDTA, they are unable to assemble correctly and are therefore nonviable. When this same 
experiment was performed using a plasmid expressing wild-type gpD, the phage were EDTA 
resistant. Phage are affected by EDTA because it acts as a chelating agent. These agents are proposed 
to remove counter ions (Mg2+) that are required during phage multiplication and help to balance the 
negative charges of DNA phosphates. When these ions are removed from solution (by EDTA), phage 
are inactivated. This inactivation is likely caused by a disruption of the head shell when DNA 
expansion occurs. Therefore, when phage are lacking capsid proteins, they are even more sensitive to 
treatment with EDTA and are unable to assemble unless less than a full length genome is present 
(Wendt, Feiss 2004).   
 Similar to Sternberg and Hoess, Mikawa et al. (1996) also demonstrated that gpD could be 
supplied in trans via plasmid complementation. This group determined that the plasmid copy number 
(level of expression) also affected the viability of D- phage when grown on a nonsuppressor strain, 
where a low copy plasmid supplying gpD showed weak phage resistance to EDTA; gpD supplied by 
a high copy plasmid made phage almost completely resistance to EDTA and phage viability was close 
to that of the phage being grown on a suppressor positive strain (91.3% recovery). In addition, they 
also determined that fusion proteins supplied by a plasmid caused phage to be more sensitive to 
EDTA than if they were grown on hosts expressing native gpD. This is consistent with the conclusion 
that when only fused protein is supplied, not all gpD sites are occupied (Mikawa, Maruyama & 
Brenner 1996). 
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In order to determine the effects of over expression of eGFP on overall viability of the 
bacterial cell, all strains that carried pKS1 were grown at various temperatures and compared with the 
same host containing just the backbone plasmid (pPL451). Taken as a whole, no discernable 
differences were seen when cells were grown on antibiotic and only a slight difference in titre was 
observed when comparing to backbone only. These findings suggest that there was only a very minor 
toxicity effect generated by any level expression of D::eGFP from pKS1, although very minor, the 
trend of decreasing toxicity relative to the plasmid backbone suggests that over-expression purports 
some toxicity to the cell as temperature (and expression) increases.  
GFP has been displayed on E. coli, yeast, hepatitis B, baculovirus, T7, adenovirus, and many 
other biological entities (Velappan et al. 2010). In order to test the ability of GFP to be detected 
within bacterial species, Pinheiro et al. (2008) chromosomally integrated a single copy of wild-type 
GFP or a modified gfp gene using a transposon into a strain of E. coli and Salmonella. Visualizing 
using a simple UV light (366 nm), they were able to show that the strains carrying the gfp cassette 
were easily differentiated from their non-fluorescent parental strains, and in addition cells remained 
viable, displaying the strongest fluorescence after 48 h incubation (as opposed to 24 h, incubations 
performed at 37° C). These levels were also compared and were akin to plasmid-borne expression 
system. They also found that when the construct was under the control of cI857, cells grown at 42° C 
after integration of a single copy, did not exhibit any detectable fluorescence after 3-5 h. The authors 
speculated that fluorescence could be potentially observed after longer periods of incubation from the 
single gene, but the metabolic stress on the cell being grown at such a high temperature likely 
prevents visible levels (Pinheiro et al. 2008). These results may make a case for growing the cells for 
longer periods of time (48 hr) in order to achieve maximal levels of fluorophore expression, but this is 
not advantageous when attempting to maximize phage titres as they peak after only a few hours 
(liquid lysate) or at the very most after a 24 hr incubation (plate lysate). These details are also 
important to consider when examining cellular expression evidence at high temperatures over 
prolonged periods as well as when examining the presence of fluorescent signal. In addition, when 
comparing the results in the next section, differing optimal eGFP, phage and cellular expression and 
growth conditions may also have an impact on the final phage decoration.  
Interestingly, only the 37° C pKS1 culture showed any strong eGFP expression, compared to 
the more gradual expression profile that was expected, based on λ cI857 repressor stability. Even 
when the temperature range was decreased, similar results were observed (compare Figures 9A and 
9B). These results suggest that there is a threshold for cI857 repressor binding at a qualitative level; 
there is no incremental increase in eGFP expression as temperature rises from 30° C to 37° C, but 
rather a surge of expression between 35° C and 37° C. However, this is difficult to confirm since the 
use of a gel doc filter is not very sensitive and low levels of expression are hard to detect due to the 
presence of considerable background. These data also agree with the complementation data discussed 
above where the greatest levels of complementation (and fluorescence) were seen at temperatures 
above 35° C (at 37° C and 39° C). The complementation data allow for a greater level of sensitivity 
though and present a repressor profile that most closely reflects the traditional functionality of cI857 
where temperature’s effect is gradual and not resembling of an on/off switch (Figure 9).   
 Loman et al. (1990) examined the use of the cI857 temperature-inducible repressor for the 
expression of heterologous fusion genes. They were able to determine that cells were repressed at 29° 
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C but not at 32° C, as was conventionally thought.. Furthermore, at the upper end of the induction 
scale, 42° C, not only does downstream expression occur, but intracellular insoluble aggregates and 
inclusion bodies may form in addition to the increased presence of proteases that are encoded by heat-
shock genes induced at 42° C. Loman et al. (1990) concluded that the relative downstream expression 
is a result of both temperature and the induction period. For example, they detected protein after 2hrs 
at 32° C and the amount detected increased as temperature increased, but at 6hrs the accumulation 
peaks at 36° C, meaning that after long periods of incubation, the accumulation of protein is greater at 
lower temperatures. This can be explained by the fact that the rate of protein synthesis is still greater 
than the rate of proteolysis at these lower temperatures. At temperatures above 36° C, the proteolysis 
offsets the gain from protein synthesis due to increased repression and overall protein production was 
lower than that obtained after 2 h or that obtained by lower temperatures over the same induction 
period (Lowman, Bina 1990). These facts informed my choice for the temperature range that was 
chosen for the cellular and phage experiments and suggests that the mid-range, and optimal phage 
temperature (37° C), will provide the greatest eGFP expression and create an environment for 
maximal gpD::eGFP production.   
 Villaverde et al. (1993) also examined the cI857 inducible repressor at temperatures between 
30 and 42° C using a plasmid-based system that expressed β-galactosidase as an indicator of gene 
expression from the regulated promoter. They found that no gene expression was detected at 
temperatures below 32° C, except through analysis by Western Blot, where a very slight band was 
observed at 28° C. These findings agree well with the results obtained by Loman et al. (1990). This 
group also found a lack of linearity between temperature and product yield, where at temperatures up 
to 36° C the repressor was not denatured very efficiently. They also found that over long incubation 
periods (>20hrs), temperatures below 42° C (38° C, 40° C), showed nearly constant values, whereas 
at 42° C, lower than expected levels were observed, which they also attributed to cell death. In their 
experiments, the ideal temperature for induction (repressor denaturation) was 42° C, whereas for 
greatest yield of protein product, a temperature of 40° C was more appropriate (Villaverde et al. 
1993). Finally, it is widely known that wild-type GFP folds very inefficiently at temperatures above 
25° C, leading to insoluble protein and the absence of fluorescence. Even mutated forms of GFP, such 
as eGFP, still fold very inefficiently at experimental temperatures such as 37° C. In order to assess the 
reporter capability of GFP, Scholz et al. (2000) compared the expression of a GFP mutant to that of 
the lacZ gene. Through their experiments they were able to determine that expression of gfp was 
almost identical to that of lacZ demonstrating that gfp can be effectively used to quantify gene 
expression in vivo. One important determinant this group uncovered was the presence of an inner 
filter effect that limits the range of fluorescence intensities, where reliable reporting of GFP molecule 
number is no longer possible. This effect seems to occur in scenarios that produce high concentrations 
of GFP, where there is then either self-aggregation of fluorescence, increased overlap of absorption 
and emission spectra or a higher total absorbance of cells expressing GFP. They also realized that 
certain GFP molecules exhibit maximum fluorescence at different excitation and emission 
wavelengths and since the filter that was used in these experiments only provided a single excitation 
and emission, it could have decreased the sensitivity of the visual fluorescence (Scholz et al. 2000). 
These previous findings represent important considerations impacting the data shown here, with 
respect to expression environments and factors that influence fusion expression and display. These 
studies contrast the use of an inducible repressor and a downstream fluorescent translational fusion. 
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The two variables together however, can counteract each other—at extreme temperatures, non-
optimal protein expression is achieved, but both seem to be in agreement that a temperature such as 
37°C, will give rise to the greatest expression over long incubation periods, consistent with the 
complementation and cellular data presented here. These points along with the narrow temperature 
specific release of the cI857 repressor give insight into why a sudden surge of expression was 
observed in the data presented here, and the fact that some recorded values are slightly off trend as all 
of these factors may not be acting consistently.  
3.3 Bi-dimensional genetic approach to the control of D::EGFP expression by 
λ lytic phage display 
3.3.1 Assaying suppression and complementation of the Dam15 mutation 
I next assessed the effect of both the suppressor type and a cI857 activity on the level of gpD::EGFP 
decoration of λF7. To determine the capability of each suppressor to suppress the Dam15 mutation 
and the temperature-regulated D::eGFP expression plasmid to complement for the mutation, I 
measured λF7 viability under permissive and non-permissive conditions. Each assay was paralleled 
by the negative control plasmid, pPL451, to ensure that the plasmid backbone was not influential on 
phage viability.   
Table 10: Efficiency of Plating of λF7 on [pPL451] and [pKS1] on different suppressing hosts at 
various temperatures 
Host Strain1 30°  C 32°  C 35°  C 37°  C 
W3101 [pPL451] 4.06 x 10-6 4.98 x 10-6 1.83 x 10-4 1.76 x 10-6 
W3101 [pKS1] 1.22 x 10-4 1.79 x 10-4 7.89 x 10-5 2.21 x 10-4 
W3101 supD [pPL451] 8.82 x 10-5 6.52 x 10-5 1.50 x 10-5 9.45 x 10-6 
W3101 supD [pKS1] 8.07 x 10-5 4.93 x 10-4 9.75 x 10-3 4.93 x 10-4 
W3101 supE [pPL451] 0.031 0.12 0.075 0.025 
W3101 supE [pKS1] 0.41 0.18 0.045 0.13 
W3101 supF [pPL451] 0.010 0.103 0.042 0.041 
W3101 supF [pKS1] 0.046 0.15 0.025 0.13 
1 N = 2, each eop is averaged from two separate trials 
2 All experiments were performed using λDam15 (λF7)  
 The basis of the bi-dimensional decoration strategy infers that different suppressors will 
suppress the Dam15 mutant phage λF7 to varying degrees based on the functionality of the 
substituted amino acid for the amber UAG codon as each suppressor in reality imparts a different 
peptide variant of gpD. The ability of the host strain to suppress the Dam15 mutation and incorporate 
wild-type D protein into the capsid provides the basis for the first dimension of decoration control. 
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The second dimension is based upon the expression level of D::eGFP expressed from the pKS1 
plasmid, which is regulated by the temperature-sensitive cI857 repressor (Table 10).  
 A significant increase in eop was not observed across temperature for any of the suppressor 
or nonsuppressor strains, suggesting that the presence of the in trans fusion peptide does not 
complement well for the Dam15 mutation. The most significant change in eop was observed for the 
strongest suppressors (SupE and SupF). This result could be expected since the presence of no wild-
type gpD in the nonsuppressor and low suppression in supD could negatively impact phage assembly 
and viability when not all gpD sites are occupied and there is no or a weak presence of wild type D. 
This is confirmed when examining the nonsuppressor, which showed no change across temperature. 
The SupD was close behind displaying the weakest suppression, with many orders of magnitude 
lower suppression being observed as compared to SupE and SupF, but there does appear to be more 
noticeable difference across temperature, with 35 and 37° C showing the greatest difference (100-
fold). This finding suggests a synergy between the gpDQ68S derivative generated by SupD 
suppression of the Dam15 mutation and the gpD::eGFP fusion expressed at these higher 
temperatures. Overall, the presence of a strong suppressor allowed for the greatest viability, 
approaching that seen on BB4 but an order of magnitude lower. This is likely due to the fact that the 
BB4 reference strain is a double suppressor (SupE SupF), while SupE and SupF each only possess a 
single suppressor gene. Having two suppressor genes greatly improves the chance of producing a 
functional gpD protein. In addition, due to such low viability, it was very difficult to determine titres 
for W3101 and SupD since phage viability was greatly affected by the lack of suppression and 
potentially the increased presence of fusions per capsid. The data above suggest that the degree of 
complementation and the degree of suppression can greatly impact the eop data, which is most 
evident at the extreme temperatures, where theoretically one could be more dominant than the other 
(suppression at lower temperatures and complementation at higher temperatures). The data does 
support this when examining the increase in eop when using the strong suppressors at low 
temperatures where complementation would be all but absent due to a high level of repression. There 
is also a slight trend towards an increasing eop as temperature rises in the weak suppressor (SupD) 
and nonsuppressor (W3101), but viability may also be counteracted by the lack of wild type D being 
integrated into the capsid.  
 A few data points deserve special comment: SupE 30° C and 35° C for SupE and SupF. 
These results do not follow the general expected trends. This could be due to the low number of trials 
that were performed (N=2). New results by our group demonstrates that an increase in eop is clearly 
observed as temperatures rise, the greatest values are achieved at lower temperatures for strong 
suppressors (SupE, SupF) and when observing the weak and nonsuppressor (SupD and W3101) the 
maximal eop is achieved at 37° C (see Appendix A for Table 2) (Nicastro, Sheldon, El-zarkout, 
Sokolenko, Aucoin, Slavcev unpublished). The discrepancy between this study and the new data 
could be attributed to improved lysate preparation, particularly with respect to shortened induction 
times that maximize D::eGFP expression. 
3.3.2 Determination of qualitative phage decoration with eGFP by Fluorescence 
I next sought to qualitatively assess the fluorescence of phage constructed under a high D::EGFP 
expression in various suppressor hosts. Assays were performed to visualize the fluorescence of 
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gpD::EGFP-decorated phage passaged at 37o C through the suppressor or nonsuppressor strains 
carrying pKS1. Figure 10 shows the fluorescence of phage grown on each suppressor strain as 
indicated by the letter that appears in the leftmost well of the row. The phage dilution that appears 
above the top wells indicates the titre of each column. Fluorescence was then compared, where a 
noticeable signal was only observed for SupD and the nonsuppressor at high titres (108, 107 and 108 
respectively), with a significantly stronger signal being observed for SupD. This result is an 
underestimation since a smaller volume was loaded as compared to the other samples (1 mL vs. 5 
mL), the actual relative fluorescence would be even greater when examining total phage per well 
(equal volume).  
 
 
Figure 10: Level of eGFP expression across titre 
All samples were prepared using λF7. Each row left to right is a single suppressor strain as indicated by 
the letter that appears in the leftmost well of the row. The number that appears above the top wells 
indicates the titre of the lysate in each column (top to bottom). Each whole lysate was diluted to 1 x 103 
pfu/mL, then 5 mL of each sample was loaded to the corresponding well and the relative visualized 
fluorescence was compared. All lysates were prepared at 37° C. For W3101 supD [pKS1] 108 only 1 mL 
instead of the usual 5 mL was loaded.  
 A comparison was then made of the effect of temperature on fluorescence, (Figure 11) where 
lysate titres were standardized and compared when expression of gpD was off (30° C) and on (37° C). 
Only the SupD and the nonsuppressor showed any noticeable level of fluorescence at either 30 or 37° 
C. The result observed for the nonsuppressor at 37° C was expected as gpD was only supplied as the 
gpD::eGFP fusion. The results achieved for SupD on the other hand were less expected, especially for 
30° C, as fluorescence observed here would indicate leaky expression of cI857 at low temperatures. 
This leakiness was however not seen in the nonsuppressor. This finding supports previous evidence 
that the presence of weak suppression may confer a more appropriate environment for maximum 
decoration of fused protein as opposed to the lack of suppression and wild-type gpD. This model 
supports the difference seen between SupD and the nonsuppressor preparations at 30° C, where the 
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lack of any wild-type D could decrease phage viability enough to eliminate any signal. It was difficult 
to visually compare the level of decoration since the standardization titre had to be set at 1 x 107 




Figure 11: Effect of temperature on eGFP decoration 
A comparison between the effects of temperature on fluorescence. Lysates of λF7 were prepared at 30° 
C (top) and 37° C (bottom) and standardized to 1 x 107 pfu/mL on various suppressors. The letter in the 
top row indicates the suppressor strain used to prepare the lysate. λF7 lysate grown on BB4 and TN 
buffer were used as controls and were only placed in the single well.   
3.3.3 Discussion 
SupD suppression of the Dam15 mutation proved to confer the lowest viability to λF7, supported by 
the fact that plaques generated by λF7 were tiny, indicating a low burst size too. However, this mutant 
strain provided a superior gpD::eGFP decoration environment for λF7 as evidenced by the highest 
level of relative fluorescence. SupE and SupF were found to be essentially equal in their ability to 
suppress the Dam15 mutation, which was also surprising given the difference between glutamine and 
tyrosine in chemical structure. This difference may impact size and polarity, and is even more 
surprising since the insertion of glutamine agrees with the native polypeptide sequence of λ D. SupE 
was previously found to be the best suppressor of this mutation substituting glutamine at the stop 
codon, while supF substitutes tyrosine, a far bulkier and polar amino acid. Great variation in eop of 
λDam15 on the wild type (Sup—) and suppressor derivatives was observed. It is important to note that 
complementation by the D::eGFP plasmid cannot be measured in suppressors by eop assays, but 
rather by changes in the cellular ratio of λ gpD to gpD::eGFP and varying degrees of phage 
decoration. Across temperatures eop’s did not change much for both the nonsuppressor and SupD 
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suppression alone. When examining the stronger suppressors it is evident that at lower temperatures 
viability is not compromised. New unpublished data by our group indicates that the optimal 
temperature for decoration of λF7 by gpD::eGFP when passaged through SupD and the 
nonsuppressor appears to be 37° C. Furthermore, since complementation of the Dam15 mutation by D 
and D::eGFP is quite efficient at higher temperatures, as indicated by the signals produced by SupD 
and the previous cellular data indicating rates of expression, the results attained with the 
nonsuppressor strain are unexpected. They further suggest that a 100% fusion decoration strategy is 
not ideal for maximal viability and that assembly is impacted in the absence of wild-type gpD 
(Nicastro, Sheldon, El-zarkout, Sokolenko, Aucoin, Slavcev unpublished).  
 Taking into consideration the results seen in Figures 10 and 11 the increased fluorescence 
observed for SupD preparations, despite these lower titres, could be due to lower eop yields arising 
from interference in phage adsorption due to high levels of decoration. Again, the difference in SupD 
over Sup— supports the case that the presence of some (very few) gpD or similar derivatives provides 
the optimal scenario with respect to phage viability and phage decoration. This is corroborated by 
new data generated by our group (Table 2 of Appendix A) (Nicastro, Sheldon, El-zarkout, Sokolenko, 
Aucoin, Slavcev unpublished).  
 When attempting to achieve high-density display, many factors may contribute to success. 
The results of the assays here suggest that the maximum level of eGFP decoration cannot be achieved 
by the gpD::eGFP fusion alone, and performs best in the presence of the gpD Q68S protein. There is 
evidence to indicate that mosaic strategies may be the most effective in achieving high-level display 
in lytic display systems. High-level Soc expression in T4 results in inclusion body formation that is 
lethal to the host. A soluble form of Soc is rapidly degraded by proteolytic activity (Forrer, Jaussi 
1998). Zucconi et al. (2001) looked at the high-density display capabilities of λ and its ability to 
display large proteins on its capsid as compared to other phage such as T7. This inherent flexibility 
makes λ a much more desirable fusion partner. Correspondingly, T7 is designed to display fusions at 
a low density for a reason related to the phage assembly process, and density of the hybrid capsid 
protein depends on protein size. This work also reported that λ is not only capable of displaying large 
proteins via gpD fusions, but can do so at a density where approximately 90% of the incorporated D 
protein is a fusion (Zucconi et al. 2001). Yang et al. (2000) also tested a variety of gpD fusions with a 
maximum size of 425 amino acids, fusing them to either terminus; all were able to complement a gpD 
mutation. Even though these fusions all required sizeable linkers, they were also able to show that the 
fusions occupied most, if not all binding sites. However, they did indicate that it is likely that a certain 
degree of proteolysis did occur, that would in turn generate some wild-type gpD to be displayed at 
some sites in vivo (Yang et al. 2000).  
The optimal temperature (37o C) to best complement λF7 with D expressed from pPL451 was 
the temperature at which almost all cI857 repressor activity is eliminated and expression of the fusion 
is directed by the λ PL promoter. Interestingly, and unexpectedly, phage grown on SupD expressing 
D::eGFP proved to be the most highly decorated, exceeding even that of the nonsuppressor, 
originally intended to be a positive control for decoration. This finding was surprising since 
theoretically phage can only be decorated by the D::eGFP protein due to the lack of Dam15 
suppression in this strain. However, even a ten-fold phage reduction (107 Sup D vs 108 W3101) 
exhibited a greater fluorescent signal. A possible explanation for this result is the possible difference 
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in eGFP functionality versus eGFP decoration, where over-decoration may result in improper folding 
and fluorophore functionality, or signal quenching do to the close proximity of fluorophores (Dai et 
al. 2008). 
Display of superfolder GFP (sfGFP) on the capsid of a phage has been previously explored 
using different filamentous phage display vectors (Velappan et al. 2010). In this study the authors 
assessed correct folding and display of sfGFP through fluorescence and antibody recognition. They 
found that there was little correlation between phage fluorescence and a positive antibody (ELISA) 
test (Velappan et al. 2010). Further studies were then performed to examine the antibody binding of 
eGFP. In regards to this study, it will be interesting to note if a similar trend in the level of expression 
exists (through Western Blotting) as it does with the recently discussed eop and fluorescent data. Dai 
et al. (2008), utilized T7 as a display vehicle and assessed its ability to correctly display GFP-based 
cytoplasmic proteins that were know to be poorly expressed by traditional phage display. This study 
concluded that fusions confirmed to be present on the phage surface (via Western Blot) do not 
necessarily fold correctly. They also determined that the fluorescence of free protein was higher than 
that of displayed protein. This was attributed most likely to quenching due to an interaction between 
the two fused proteins (Dai et al. 2008). These caveats are important to consider when examining the 
results of this research study. Since no steps were taken to eliminate free protein from solution, 
monomeric protein (gpD::eGFP) could contribute to the qualitative results, due to its presence in the 
lysate adding to visualized fluorescence. That aside, the level of expression should be the same in 
each host strain since the plasmid is identical and this additional fluorescence should be eliminated as 
background.    
Other single-molecule fluorescence techniques have been employed to count fluorescent 
proteins per phage and determine display levels. Methods that can distinguish between soluble and 
phage-bound fluorescent proteins directly have proved more accurate for quantifying display levels 
than bulk methods, which contain non-infectious phage and soluble protein. Two such methods that 
have been employed when examining the number of GFP molecules present on T7 are fluorescence 
correlation spectroscopy (FCS) and photon antibunching (Dai et al. 2008). In addition, there has also 
been a study published recently using fluorescence-activated cell sorting (FACS) to quantify the 
number of eGFP molecules present on λ. This type of analysis allows for a much greater 
discrimination of phage populations and will allow for greater analysis of sub-populations and 
determinations of a true numerical difference when varying environmental conditions are applied 
(Sokolenko et al. 2012).    
3.4 Assessing eGFP phage decoration  
3.4.1 Whole Lysate Filtration 
Since the D::GFP fusion is plasmid encoded and can be expressed at high levels by thermal induction 
(Figure 3), much of which may not be incorporated into assembling phage, the possibility of free 
protein in the cell lysate contributing to phage lysate fluorescence had to be addressed. To purify 
lysates and remove any contaminating protein, protein analysis data was collected following 
centrifugal filtration of whole lysates through three different molecular weight cut off filters. Titres of 
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lysates were measured before and after processing (Table 11) to ensure that filters were maximized to 
capture large gpD::eGFP molecules, while allowing phage passage. In addition, absolute protein 
concentration of each filtrate was measured to assess how much free protein had been filtered. The 
process by which lysates were membrane filtered is shown below (Figure 12).  
 While the 100 KDa filter allowed passage of ~400 phage per mL, the 50 kDa filter appeared 
optimal to remove residual protein without compromising any loss of phage when comparing the 
titres of different samples that were analyzed using various molecular weight cut offs. Results 
indicated that the ideal filtration optimization appeared to be with a 50 kDa filter. The 100 kDa filter 
used for the λF7 phage that was grown on W3101 supD [pKS1], which generated filtrate of 4 x 102 
pfu/mL. Lysates were filtered in order to remove residual cytoplasmic gpD::eGFP monomers, which 
were retained through filtration with the 10 and 30 KDa filters.  
 
Figure 12: Lysate filtration of EGFP decorated λDam15  
Filtration process taken with each lysate in preparation for protein analysis.  
Table 11: Whole Lysate Filtration for Protein Analysis 






Protein Conc. of 
Filtrate OD280 
(mg/mL) 
W3101 [pKS1] 7.00 x 107 2.2 x 108 50 19.502 
W3101 supD  
[pKS1] 
4.00 x 107 2.0 x 107 100 16.930 
W3101 [pKS2] 9.90 x 108 2.5 x 1010 50 21.116 
W3101 [pKS1] n/a < 1 x102 30 6.435 
W3101 supD  
[pKS1] 
n/a 4 x 102 30 9.572 
1MWCO = Molecular Weight Cut Off 
2The flow through from use of the 30KDa filter was also refiltered with a 10KDa filter and the concentrations were W3101 [pKS1] = 9.648 
mg/mL and W3101 supD [pKS1] = 10.212 mg/mL 
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 After filtration of the flow-through from W3101 [pKS1] and W3101 SupD [pKS1], filtrates 
were observed under eGFP filters alongside their whole lysate counterparts. There was a decrease of 
fluorescence for the Sup— [pKS1] strain and strong presence of fluorescence for the W3101 SupD 
[pKS1] strain. Both strains were then further filtered using a 30 kDa and 10 kDa filter and the 
resulting filtrates flow through were compared with the first and noted to yield a similar result to the 
initial filtration. This data agrees with the results from Table 11 above, as filtrate flow through from 
the later strain (SupD) contained phage at approximately 4 x 102 pfu/mL post filtration whereas the 
W3101 [pKS1] did not yield any viable phage.   
 Figure 13, shows the comparison of primary lysate fluorescence to lysate filtrate. The level of 
fluorescence was standardized using λF7 as the negative control background signal. The filtrate of the 
W3101 SupD [pKS1] phage preparation through the 100 kDa filter exhibited detectable fluorescence 
at 2 x 107 pfu/mL. The fluorescence signal should be primarily due to gpD::eGFP monomers within 




Figure 13: Comparison of fluorescence from filtered and unfiltered lysates  
Comparison of fluorescence between prefiltered lysates and filtrates. Each phage preparation is labeled 
indicated by the strain on which the lysate was grown. Subscript F indicates post filtration. λF7 and TN 
were used as a phage and buffer control, respectively.  
 Next, the levels of fluorescence observed from the lysate filtrates were compared. Figure 14 
shows a comparison of the both filtered phage pre and post 30 kDa and 10 kDa size exclusion 
filtering. Only the pre 30 kDa lysate for SupD showed any signal, indicating that it was the only 
lysate that contained a significant amount of eGFP assuming that free monomeric gpD::eGFP was 
retained by the 30 kDa filter. The background level of fluorescence was determined by the use of a 
control phage grown on W3101 [pKS2]. 
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Figure 14: Fluorescent signal from lysate filtrates  
A comparison of collected lysate filtrates. Top row: W3101 [pKS1] preparations. Bottom row: W3101 SupD 
[pKS1]. Column 1: Flow through from before the 30 kDa filtration; 2: Filtrate following 30 kDa filtration; 3: 
Filtrate following 10 kDa filtration. Background level of fluorescence was determined based on W3101 
[pKS2 (pD+)].  
3.4.2 Western Blot Analysis 
The GFP fluorescence assays suggest that λ F7 passaged through SupD expressing D::egfp  provided 
the strongest decoration of λ phage by gpD::eGFP. However, it is important to note that fluorescence 
is related to protein function, and may not parallel the actual fusion protein insertion. For instance, 
over- decoration may result in quenching, steric hindrance or other unidentified hindrance of 
functionality, as mentioned in above sections regarding GFP. To determine actual eGFP density per 
phage, immunoblotting was conducted on phage lysates passaged through the two highest 
fluorescence yielding strains under induced conditions (37o C): Sup— and SupD, both carrying the 
inducible D::eGFP [pKS1] plasmid. Proteins were separated electrophoretically by size, then 
immunoblotted using a polyclonal primary anti-GFP antibody and stained by two different 
approaches (Figures 15 and 16). The intensity of the eGFP band at 33 kDa from SupD [pKS1] 
following filtration via 30 kDa filter was observed to be remarkably stronger than that of W3101 
[pKS1] when the same amount of whole protein is loaded. This finding suggests that SupD [pKS1] 
phage preparation may confer a greater eGFP decoration capacity to the λF7 phage. Figure 15 shows 
the presence of gpD::eGFP within the filtered lysates that is decorating the phage. The predicted size 
of the upper polypeptide is consistent with gpD::eGFP, while the lower band migrated at a rate 
consistent with the size of native eGFP. As a polyclonal antibody was used for detection, it is possible 
 white light  fluorescence 
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that this lower polypeptide is due to cross-reactive staining of a different phage protein, but this is 
unlikely. The lower polypeptide more likely represents a derivative generated during the sample 
boiling step of the immunoblot protocol or could potentially been caused by proteases within the host 
cell that have caused the breakage before samples were prepared. In either case the linker between 
gpD and the fused eGFP represents a weak point in the modular protein that results in dissociation 
between the two components.   
 
 
Figure 15: Fusion gpD::eGFP decoration of λDam15 phage passaged through Sup— and Sup+ 
D::eGFP expressing strains. 
Lanes 1, 7, 15: size markers. L2:  W3101 [pKS1], L3: W3101 supD [pKS1]. L4: W3101 [pKS2], L5 and 6: 
Filtrate from the initial samples filtered with a 30 kDa filter. L8: blank. L9 - 14: eGFP standard at 50 ng, 10 ng, 
1 ng, 50 pg, and 100 pg respectively. For lanes 2, 3, and 4, 200 ng of absolute protein was loaded. For lanes 5 
and 6, 100 ng of absolute protein was loaded. Membrane image shown on left, stained with Ponceau S; 
membrane image on right, detection by fluorescence. 
 The filtrates following passage through a 10 KDa exclusion filter were analyzed in a similar 
blot (Figure 16). Once again, the level of eGFP decoration observed upon passaging of the λDam15 
phage through the W3101 supD [pKS1] strain was qualitatively much greater than that seen on 
W3101 [pKS1]. The 10 kDa filtrates lost the lower eGFP band originally observed from the 30 kDa 
flow through (Figure 15). This may be due to the removal of all dissociated eGFP by the 10 kDa 
filter, retaining only gpD::eGFP. While this finding likely indicates the presence of gpD::eGFP 
monomer in the whole lysate, it was not substantial enough to signal notable fluorescence for the 
control phage (Figures 9 and 10), indicating that in prior qualitative studies the majority of 
fluorescence observed was indeed conferred by the decorated phage and not free gpD::eGFP fusion 
protein.  
gpD::eGFP (~43 KDa) 
eGFP (~33 KDa) 
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Figure 16: Protein analysis of gpD::eGFP monomer present within the sup— and sup+ filtered 
lysates 
Lanes 1, 9, 15: size markers. L2:  W3101 [pKS1], L3: W3101 supD [pKS1]. L4: W3101 [pKS2], (negative 
control for eGFP). L 5 and 6: Flow through from the initial samples filtered with a 30 kDa filter. L10 - 15: eGFP 
standard at 50 ng, 10 ng, 1 ng, 50 pg, and 100 pg respectively. For lanes 2, 3, and 4, 200 ng of absolute protein 
was loaded. For lanes 5 and 6, 100 ng of absolute protein was loaded. Lanes 7 and 8 are 10KDa filtrates of 
W3101 [pKS1] and W3101 supD [pKS1]. As in Figure 15, the left image of Figure 16 is the membrane stained 
with Ponceau S and the right image is detection by fluorescence. For lanes 7 and 8 100ng of absolute protein was 
loaded.  
3.4.3 Discussion 
In solution, λ gpD exists as a monomer even at very high concentrations, and trimer formation of 
native or fusion D proteins only occurs through cooperative binding; it is facilitated by λ gpE during 
prohead assembly (Hayes, Gamage & Hayes 2010, Yang et al. 2000). With this in mind, in order to 
eliminate the majority of free gpD and gpD::eGFP in solution before immunoblotting was performed, 
phage lysates were filtered through size exclusion columns. Here, titers were compared between pre 
and post-filtered lysates to determine whether phage were being filtered as well. A study by Vaccaro 
et al. (2006) involves purifying phage particles first by standard PEG precipitation, before capturing 
viable phage by affinity-purification using an anti-V monoclonal antibody. The purpose of the 
additional step was to eliminate free recombinant gpD from solution since it is also precipitated by 
PEG with phage particles. A similar intention was desired in this study through the use of filtration, 
rather than through the use of antibodies.   
 A fluorescent signal was evident in the flow through after passage through the 30 kDa filter, 
which may indicate that this size exclusion treatment did not remove free gpD::eGFP from the lysate, 
or that another cleaved species of eGFP was present upon preparative treatment, since this size of 
filter should capture gpD::eGFP monomers.  
Similarly to the fluorescence assays, two distinct bands were noted in all assays of decorated 
phage or filtrates. The 43 kDa protein denotes gpD::eGFP, while the smaller identified species (~33 
kDa) aligns with a cleaved eGFP. This could be a possible point of cleavage or breakage as, there is 
only a short linker that separates gpD and eGFP and during the SDS and boiling process or within the 
gpD::eGFP (~43 KDa) 
eGFP (~33 KDa) 
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host cell at the hand of proteases, the two proteins could separate through a break of this linker. More 
specifically, there is also a Lon protease cleavage site at this location as well, that may cleave at high 
temperatures. This may also be responsible for the two distinct bands that are observed here. 
Interestingly, the filtrate from the 10 kDa filter retains only gpD::eGFP, eliminating the smaller 
species, which should occur, since the fragment is 33 kDa.  
 GFP has proven to be a suitable fusion protein and reporter. In addition, certain mutants have 
shown to be relatively stable in the presence of some proteases and protein denaturing solutions such 
as 1% SDS, where studies have observed that it also does not lose its fluorescence (Aoki et al. 2003). 
Fused GFP species were observed to migrate to different positions, where the molecular mass of the 
fused polypeptide was lower than that of the nonfused counterpart. This result may be caused by the 
β-can structure of GFP, where the structure is not destroyed by SDS and the mobility of GFP is slow 
and the fused protein moves more quickly (Aoki et al. 2003). In addition, the fluorescence intensity of 
GFP can increase or decrease depending on the polypeptide that is fused. Here, the expression level 
was not consistent with observed fluorescence, which depends on the amount of the active form 
present. Aoki et al. (2003) further speculated that the amount of active form depends on the 
hydrophilicity of the fused polypeptide where there is a positive correlation between fluorescence and 
hydrophilicity. Velappan et al. (2010), in their work with display of stable GFP on filamentous phage, 
were able to apply a commercially available monoclonal antibody that recognized a conformational 
epitope destroyed by SDS and boiling. The use of a similar antibody could provide insight into 
whether or not an active or inactive form of eGFP is present in solution after SDS treatment and 
boiling.  
 To quantify the amount of protein and therefore the number of fusion proteins per phage 
Gupta et al. (2003) and Vaccaro et al. (2006) used densitometric scanning of a Western blot to 
determine that the total copies of fusion protein per phage particle was approximately 400 gpD 
fusions/phage. Here, the N-terminal comprised 48.8% of recombinant gpD proteins, while the C-
terminal constituted up to 88.4%. This application extends the utility of immunoblotting to density 
quantification of gpD::eGFP fusions present on each phage capsid. Since, we were unable to 
determine the exact amount of protein (gpD and eGFP) as lysates also contain phage structural 
proteins, this method may prove useful since it would not consider the additional protein content that 
is present within the lysate that is not eGFP.  
3.4.4 Conclusion 
By immunoblotting filtered lysates, additional insights were garnered with respect to density of fused 
protein on the capsids of decorated phage constructs. Firstly, when phage lysates were filtered to 
remove gpD::eGFP monomers in solution, a significant level of fluorescence was observed in the 
flow through, indicating that monomers were present and they contributed to the overall fluorescence 
observed in previous experiments. Through the use of an eGFP-specific antibody, the presence of 
eGFP was confirmed to be present on the phage capsid with two distinct polypeptides appearing on 
the blot, one the size of gpD::eGFP (43KDa) and the second, eGFP (33KDa) alone. It is possible that 
this second band was generated through the cleavage of gpD::eGFP, dissociating eGFP from gpD due 
to breakage of the short peptide linker during SDS treatment or boiling during sample preparation. 
This additional (lower) band did not exist in flow through samples (that were filtered with a 30 kDa 
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filter, that would not allow larger phage particles to be passaged), further supporting the above theory. 
Purification could be dramatically improved through the use of an affinity binding strategy, such as 
utilizing the major tail protein gpV to avoid the need to filter samples. This would eliminate the 
potential loss of titre from filtering as well as reduce cellular contamination of unincorporated fusion 
proteins. 
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Chapter 4 Conclusions and Future Directions 
4.1 Final Conclusions 
4.1.1 Overall Objectives and Achievements  
The global objective of this research project was to create a bacterial model for the controllable 
expression of peptides/proteins on the major capsid protein (gpD) of bacteriophage λ. The creation of 
such a modifiable platform system of phage display could then be geared towards downstream 
applications such as novel biologic development (vaccines, antimicrobials) and/or targeted gene 
therapy, to name a few. In order to achieve this objective, two levels of genetic control were applied; 
a plasmid-mediated temperature inducible repressor (cI[Ts]857) governing downstream gene 
expression, and amber suppression (via SupD, SupE, SupF suppressor alleles) providing different 
translational derivatives of the major capsid protein with varying levels of functionality.  
The novel constructs that were derived from this research include: 
1. SupD/E/F bacterial isogenic amber suppressor strains  
2. The pKS1 plasmid, a multicopy D::eGFP expression plasmid governed by the temperature 
sensitive λ cI857 that imparts in trans gpD::eGFP decoration increasingly as temperature is 
raised 
3. The pKS2, a multicopy derivative of pKS1 deleted for eGFP that expresses wild-type D.  
The novel scientific results achieved through this research include: 
1. Sequencing of λDam15 allele, indicating a point mutation at 204th bp of D converting the 68th 
residue, glutamine (CAG), to an amber translational stop signal (UAG). 
2. Determination of the relative plating efficiency of each isogenic suppressor strain at various 
temperatures. As expected the nonsuppressor did not support viability of the λDam15 phage, 
and the Q68S allele generated by λDam15 growth on the supD showed very poor 
functionality compared to gpDwt (supE) and gpDQ68Y(supF).  
3. Expression of λ D from pKS2 was able to nearly completely complement for the Dam15 
mutation at induced temperatures, while observed complementation in this work from pKS1 
(D::eGFP) was far lower than its D+ counterpart. 
4. Expression of D::eGFP and D from pKS1 and pKS2 respectively, at temperatures showing 
high-level expression of D::eGFP was not toxic to the bacterial cell.  
5. Regulated expression of D::eGFP from pKS1 in combination with varied D allele 
functionality conferred by various amber suppressor strains led to different levels of λ capsid 
decoration by both wild-type and fused gpD. gpDwt (supE) and Q68Y (supF) alleles 
demonstrated comparable and best functionality as gauged by restoring viability of λDam15 
phage. 
6. Greatest eGFP decoration of phage was observed in phage passaged through the 
nonsuppressor and supD strains expressing D::eGFP from pKS1 at the inducing temperature 
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of 37° C. These constructs also appear to affect phage viability, where the presence of 
increased levels of fused protein impacts the ability of phage to assemble appropriately. 
7. Western blotting confirmed the presence of eGFP fused to gpD as well as the presence of a 
second species that may be attributed to proteolytic cleavage or breakage of eGFP from gpD. 	  
4.1.2 Supporting Literature  
4.1.2.1 Amino vs. Carboxyl Fusions and the Presence of Suppression 
The λ gpD protein is tolerant of a wide variety of protein and peptide fusions to its amino and carboxy 
terminal ends, providing great flexibility for phage display. Pavoni et al. (2004) constructed a tumor 
cDNA display library employing N-terminal fusions to gpD in order to prevent the selection of out-
of-frame fusions. Since the N-terminal fusion was upstream of gpD, if it was out-of-frame, the fusion 
would not be expressed because the downstream gpD would also be out-of-frame and therefore 
unable to assemble appropriately within the phage capsid. As such, the recombinant phage would be 
decorated solely with wild-type gpD (Pavoni et al. 2004, Minenkova et al. 2003). This study also 
utilized the λKM8 and λKM10 phage constructs, which were based on KM4 phage which can accept 
inserts of up to 3 kb in length without disturbing lambda packaging (Minenkova et al., 2003). The use 
of an N-terminal fusion and an engineered phage created an excellent environment for easy assembly 
of chimeric phage. However, N-terminal fusions, to eGFP prevented its proper folding and therefore 
fluorescence would not be possible. Our construct has similar properties to the KM phage, in that a 
two-gene system is employed, although our fusion is plasmid-mediated and controllable in nature. 
When the phage was first designed, Pavoni et al. (2004) also determined as did Zucconi et al. (2001) 
that the number of fusion proteins displayed on the capsid surface varied depending on the length and 
a.a. composition of the foreign sequence and when these fusions were expressed at the C-terminus a 
very high incorporation rate could be achieved; a similar situation exists for N-terminal fusions. 
Neither of the studies above mentioned a reduction in phage viability or an effect on phage assembly 
with the peptides they attempted to fuse (Minenkova et al. 2003, Zucconi et al. 2001). These are 
however important considerations in that they give insight into the affect the fusion has on the ability 
for D to retain functionality and thus, for phage to assemble properly and form viable phage particles.  
 To further examine differences between the N and C termini of gpD in conferring decoration 
on λ, Vaccaro et al. (2006) created fusions to a functional scFv antibody (anti-CEA) to λ’s gpD. 
Human carcinoembryonic antigen (CEA) is an oncofetal glycoprotein known to be over-expressed in 
several tumour types. In order to create these fusions, they also utilized the KM phages, λKM8 (N-
terminal) and λKM10 (C-terminal), which contain a double gene D system and a flexible linker 
between the fusion peptide and gpD. The genomic copy of D contains an amber mutation, where the 
second copy, used for fusions, has a unique cloning site at either the N or C-terminal respectively. 
When phage carrying a fusion are grown on an amber suppressor, chimeric phage that display both 
the fusion and wild-type D are produced (Vaccaro et al. 2006). While the phage described by Vaccaro 
et al. are similar to those generated by the system constructed here, i.e. chimeric phage are created 
when a fusion is cloned into either phage genome, poor control exists in their system imparted only 
by the crude competition between suppressor generated gpDwt and constitutive production of the 
fusion allele.  
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 When comparing the N and C-terminal fusions, the carboxy- fusions presented with 
unusually small plaques, which suggested that the large scFv protein was compromising phage 
assembly. In addition, titres derived from a single plaque for this phage were also significantly lower 
than that seen for the N-terminal fusion and unfused λKM8 and λKM10, where the average was 106 
PFU per plaque as compared to 103 PFU per plaque for the C-terminal fusion (Vaccaro et al. 2006). 
These results show similar trends to this work when a supD suppressor or nonsuppressor was 
employed. These observations suggested that the presence of D::eGFP at high densities might inhibit 
phage assembly, corroborated by the reduced plaque size and lower titres of this prep as compared to 
those grown on stronger suppressors. Santini et al. (1998) also observed a similar result where fusion 
of large protein domains to gpD significantly reduced the titre of phage when grown on Sup— strains, 
indicating that incorporating wild-type D protein is preferential for proper assembly, and that the use 
of suppressor strains is advantageous.  
Vaccaro et al., (2006) also performed phage stability assays, via immunoscreening, and 
observed that 1-5% of plaques generated by C-terminal fusions were larger in size and negative for 
the assay and the C-terminal fusions also had a lower titre as compared to the N-terminal fusions. 
After further investigation, it was discovered that these plaques were in fact mutants and contained 
frame shift mutations or stop codons within the scFv gene. This additional evidence further supports 
the inefficient display of the antibody as a C-terminal fusion and its effect on phage assembly. Tiny 
plaques observed in this work when phage were grown on supD, may indicate the presence of 
revertants or mutants that are seen because the lack of suppression is disadvantageous to phage 
assembly and growth. Interestingly enough, this was not observed when phage were grown on a 
nonsuppressing strain, as would be expected. Furthermore, the N- and C-terminal fusions also varied 
in their fusion density, where the C-terminal was composed of a greater percentage of recombinant 
protein than the N-terminal. These data agree with the previous observations regarding stability and 
phage assembly, further confirming that a portion of the phage must consist of wild-type gpD 
(Vaccaro et al. 2006). The significant disparity in percentages also presents a strong case for the 
success of high-density display at the C-terminal. It is important to note, that the presence of a 
suppressor, may also contribute to the overall density, since the integration of some wild-type gpD 
increase phage viability. Even though this study determined that an N-terminal fusion to a scFv 
antibody gives rise to normal plaques, with comparable efficiency to that of the wild type, they have a 
lower antibody display density. This may be due to a reduced interaction at the gpD-binding site with 
gpE and therefore lower incorporation efficiency, while still retaining the higher viability. Here we 
observe a trade-off that exists between N and C-terminal fusions, where increased phage viability is 
inversely proportional to incorporation efficiency. A similar conclusion was also arrived at by Yang 
et al. (2000) when N-terminal fusions to gpD were examined. The higher display density exhibited by 
the C-terminal fusion indicates that the presence of a large protein disrupts phage assembly (not in the 
same manner as N-terminal fusions, because a higher incorporation is observed) thereby decreasing 
phage viability due to the overloading of recombinant protein, causing the lower PFU and higher 
mutation rate. Interestingly, they report that this C-terminal phenomenon was not observed in 
previous studies where recombinant protein was incorporated with wild-type gpD again suggesting 
the role of wild type gpD in improving incorporation of the fusion. These studies did mention that 
low yields and decreased phage viability were observed when there was a greater incorporation of 
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fused protein, most likely due to the presence of a strong suppression (the source of the fusion 
protein) (Mikawa, Maruyama & Brenner 1996, Maruyama, Maruyama & Brenner 1994).    
4.1.2.2 Foundational Data for this Research Study 
Close examination of the principal research that forms the basis of the studies reported in this thesis 
reveals additional consistent observations. Maruyama et al. (1994) initially investigated the use of 
suppression as a control mechanism for the display of fusion proteins on the surface of λ. They used 
the λfoo vector that expressed a truncated form of λ’s major tail protein, gpV (mutants had been 
shown to exist where up to one third of the protein is missing), a short linker and an in-frame coding 
sequence. Phage grown on a suppressor strain produced full-length gpV with a fusion at the C-
terminus. Fusions created using this system included E. coli β–galactosidase and plant Bauhinia 
purpurea agglutin. Again, when grown on strong suppressor strains, smaller plaques were observed. 
This result was not observed when comparing the parent (λfoo) or growth on weaker/nonsuppressor 
strains. The authors hypothesized that “large amounts of chimeric fusion protein produced by the 
strong suppressor, inhibit phage assembly”. Further evidence to support the effect on phage assembly 
is the observed low yield of fusions present on the phage surface, where the majority of phage had no 
incorporation and only 1% had 3 or more fusions. A final important observation was the residual 
read-through of the amber stop codon, where trace amounts of fusion were noted when phage were 
grown on nonsuppressor strains.  
From these prior experiments, some similarities and incremental improvements can be 
observed in the results presented in this thesis. For the constructs described in the paragraph above the 
level of suppression fully controlled the presence of fused protein and therefore, the stronger the 
suppressor the greater the level of expression of the gpD allele. Initially, it was found that large C-
terminal fusions created distinctive plaque sizes and impacted phage assembly but may not influence 
yield, since gpD exists in a much greater density than gpV. In addition, the chance of residual read-
through was greatly reduced with the existence of an ochre stop codon within the eGFP sequence, 
which does not allow for residual read through after the fusion, since only amber suppression is being 
conferred by the amber suppressor host cells. Furthermore, due to the reverse construction of this 
system, where suppression supplies the gpV fusion, rather than wild type, it does not as easily allow 
for the presence of wild type gpD, which may have contributed to the reduced phage viability and 
smaller plaques. Again, the ability to control the number of fusions, on the phage capsid appears to 
impact phage assembly and phage viability.  
 Following the use of the tail protein as a fusion candidate, two separate groups studied the use 
of gpD for fusions at the same time. Sternberg and Hoess (1995) studied N-terminal fusions, and 
Mikawa et al. (1996) looked at both N and C-terminal fusions to gpD. The former used the Cre-loxP 
site-specific recombination system to incorporate fusion plasmids directly into λ, whereby phage then 
contained both a wild-type D (when grown on a suppressor) and the fusion protein was supplied by 
the integrated plasmid (Sternberg, Hoess 1995).  
Both studies demonstrated that protein could be fused to the phage capsid in vitro utilizing 
plasmid-mediated in trans complementation. Both studies also showed an inability to achieve a 
scenario where all gpD sites on the capsid were occupied by fusion proteins as phage were still 
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resistant to EDTA, indicating empty gpD sites. Sternberg and Hoess (1995) also used a plasmid 
expressing wild-type D reporting similar results to those described here, where they were able to 
restore phage viability via complementation from the D-expressing plasmid. In addition, the concept 
of polyvalency was raised, and the ability to use such a system for gene delivery where surface 
decoration could be achieved in vitro or in vivo. Moreover, Mikawa et al. (1996) showed that plasmid 
copy number does affect the level of expression and therefore ability to complement and by supplying 
only fused protein at high levels phage are still sensitive to EDTA, indicating again not all sites are 
occupied by fused protein (Mikawa, Maruyama & Brenner 1996, Sternberg, Hoess 1995). In this 
work, plasmid copy number was not used as an approach to control decoration and a high copy 
plasmid was employed for all constructs, but this may be of interest in future studies where multiple 
fusions could be incorporated simultaneously into a phage capsid. The manipulation of plasmid copy 
number could provide a third dimension of control.  
 Mikawa et al. (1996) developed a system where a peptide/protein could be fused at either the 
N or C-terminus of gpD. Genetic (amber) suppression was used to control the proportion of chimeric 
protein decorating the phage capsid. Using this system, they examined gpD fusions of β–lactamase, 
the IgG-binding domains of the Staphylococcus aureus protein A and β–galactosidase (β–gal). They 
noted that N-terminal fusions of Protein A and β–gal, yielded low recovery on a nonsuppressor host, 
indicating that the phage assembly and viability is affected by chimeric gpD fusions in the absence of 
native gpD. Interestingly, when passaged through a strong suppressor alone, this study revealed a 
greater than 100% recovery of original titre, suggesting that suppression may in fact be more or 
equally as effective as trans complementation and may incorporate proteins just as efficiently. As 
mentioned and illustrated previously, the availability of unfused molecules increases viability in 
combination with their fused counterparts compared to fused molecules alone (Mikawa, Maruyama & 
Brenner 1996). In my work, I also noted a higher recovery of phage carrying both unfused and fused 
gpD compared to unfused alone. This may suggest that 100% decoration of λ by gpD fusions cannot 
result in functional phage, and there is still a need for some wild type gpD in achieving optimal phage 
assembly. The results shown here indicate that the highest fusion density occurs through the 
combination of the fused gpD and a poorly functioning gpD derivative, such as gpDQ68S (SupD), 
thus allowing the incorporation of some unfused gpD allele, and a large portion of fused protein, as 
seen in this study with the supD strain. This argument is further confirmed when comparing the supD 
incorporation to that of both the strong suppressor (SupE and SupF) and the nonsuppressor strains, 
where increased viability is conferred by the strong suppressor but a low ratio of fused to unfused 
molecules was observed.  
 In addition, when a wild-type λ imm21 (D+) phage was plated on cells carrying the fusion 
plasmid, fusions were also incorporated into the capsid, not just wild-type gpD, which further 
suggests that plasmid-mediated complementation has the capacity to compete effectively with the 
incorporation of wild-type gpD within the cytoplasm during phage assembly (Mikawa, Maruyama & 
Brenner 1996). This is an important observation when attempting to determine what the efficiencies 
of incorporation are when comparing suppression and incorporation of various gpD derivatives 
compared to that of the fused gpD allele expressed from a temperature-regulated plasmid.  
 Like Sternberg and Hoess (1995), this group also constructed their own phage vectors, which 
in this case were modeled after λfoo, a vector that utilizes a truncated form of λ’s major tail protein, 
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gpV, a short linker and a fused protein, where phage grown on a suppressor strain produce full-length 
gpV with a fusion at the C-terminal. One of these vectors contained an N-terminal fusion (λfooDn) 
and the second, a C-terminal fusion (λfooDc). Once Protein A was incorporated, and phage were 
grown on different suppressor strains, they noted that both phage were capable of binding to a 
corresponding antibody (BSA) when the phage was passaged through a strong suppressor. The same 
phage (λfooDc) decorated with β–gal was used to estimate the number of fusions per phage as 
compared to the original λfoo. As expected a greater number of fusions were observed on a stronger 
suppressor (34.3 vs. 2.3) and both showed a greater efficiency to that of λfoo (Mikawa, Maruyama & 
Brenner 1996). This is important to note when considering the use of a display system for 
downstream applications, in that there must be a certain number of fusions present on the capsid in 
order to elicit any response, to provide utility toward any application.  
 The Maruyama (1994) and Mikawa (1996) studies used constructs where an amber stop 
codon was located upstream of the gpV/gpD fusion modulating total fusion protein incorporated on 
the capsid. As such, the level of decoration was dependent on the strength of suppression supplied by 
the host bacterial Sup+ mutant through which the phage was passaged. Overall, these initial studies 
provided a great foundation and premise for this body of work while also providing preliminary 
insight into some of the challenges that would be faced and complications that needed to be 
overcome. To build on this foundational work we sought to construct a novel display platform that 
uses multiple levels of control—1) amber suppression that supplies various unfused gpD derivatives; 
and 2) temperature regulated complementation of the gpD fusion. Utilizing the C-terminal of the gpD 
molecule allowed for high-density display, where the highest level of phage decoration was when 
high expression of the D fusion was combined with the poorest functioning gpD derivative (SupD).    
4.2 Future Directions  
4.2.1 Downstream Applications of this Research 
The intended downstream applications of this research are the construction of multivalent phage 
vaccines and/or the development of vehicles for phage-mediated targeted gene therapy. These 
applications exhibit the two endpoints of the spectrum of phage surface display control. Vaccination 
would expectedly be most effective if display saturation was reached, whereas targeted transgene 
delivery applications would require a high-level of specificity in targeting unique receptors of 
appropriate cells, where fewer and controlled fusions would be preferable. The use of this system to 
create a novel procedure for phage vaccine development will first be discussed followed by the 
practicality for use in gene therapy. Advantages of using phage in vaccine design include: 
• Feasibility of producing them rapidly in large scale for minimum cost 
• Non-infectivity toward an animal host, safety (phage can be genetically or physically 
inactivated) 
• Stability (wide range of temperature and pH) 
• Natural adjuvant activity 
• Ability to target APCs and induce both cellular and humoral immunity  
(Hayes, Gamage & Hayes 2010) 
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4.2.1.1 Use of Phage in Vaccine Development 
The use of filamentous phage in development of vaccines was explored by Bastien et al. (1997), who 
employed phage fd to display a chimeric protein with a proven protective epitope (G glycoprotein) 
against RSV. This study showed that mice acquired complete resistance to a viral challenge by the 
lack of virus in their lungs and high levels of RSV-specific antibodies. In addition, the level of 
antibody was only slightly lower than that seen when mice are immunized with whole RSV virus. 
This study also first showed that a recombinant phage can be selected directly from a random peptide 
library and used directly in protection assays (Bastien, Trudel & Simard 1997). 
 March et al. (2004) first used λ as a DNA vaccine when they immunized mice with λ 
particles encoding either eGFP or hepatitis B surface antigen (HBsAG) in the commercially available 
λ expression vector λ-gt11 (Agilent Technologies, Mississauga ON). In order to create this non-
traditional DNA vaccine, expression cassettes containing DNA from eGFP or HBsAG were cloned 
into λ-gt11 under the control of a eukaryotic promoter. The DNA was then packaged in vitro by the 
phage and propagated in E. coli. Finally, recombinant phage containing the DNA were injected into 
mice. Here the expression system allowed the DNA to be protected by the phage until safely within 
the cell. These particular constructs did not display the protein on the phage surface (March, Clark & 
Jepson 2004). Both of these modified DNA vaccine constructs were able to elicit an immune response 
in mice that were specific to eGFP and HBsAG, but results were inconsistent, suggesting that by 
displaying antigens on the surface of the phage, rather than a DNA solely format is a more specific 
and effective approach for phage vaccination. Recently, Thomas et al. (2012) developed a λ vaccine 
using a combination of cis  (via recombination) and trans (plasmid-mediated) phage display to further 
show that peptide immunization is superior to genetic immunization, where proteins elicited a far 
stronger immune response at physiological pH in higher primates and humans than genetic 
vaccination in the absence of an adjuvant, where cis complementation indicates that the gene product 
is derived from the same gene and trans complementation indicates that the gene product is derived 
from a different gene. In addition, they also developed a divalent subunit vaccine, that was a hybrid of 
both a DNA and a peptide vaccine which was far more superior than the solely peptide vaccine 
creating two separate fusions to gpD, one with GFP and the other TAT protein (protein transduction) 
from HIV1. Both fusions were constructed to the C terminal of gpD and a short linker was placed 
between the two protein domains and these were displayed on the phage surface in tandem. The same 
phage that lacked display of these two proteins was used as the DNA vector for comparison. Similar 
to the system shown here, the plasmid expressing the fusion was inducible by IPTG (Isopropyl β-D-1-
thiogalactopyranoside) and the recombineered genome was passaged through a SupF host. All 
immunization groups observed a primarily humoral response and they also found that λ itself acted as 
an endogenous adjuvant, where the phage displaying the two peptides again outperformed the non-
displaying DNA vaccine (Thomas et al. 2012). One incremental improvement seen in the system 
constructed for this research study is that the temperature-inducible promoter does not require the 
addition of any chemical inducers, but rather just a change in temperature, which simplifies the 
preparation process.  
 A second lambda-based vaccine was also developed by Hayes et al. (2010) that was slightly 
more advanced than the prior. In this construct multiple fusions to the C-terminal of gpD were made; 
one where four immunodominant regions of the porcine circovirus capsid were fused (D-CAP), a 
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second with GFP (D-GFP) and a third with SPA tag protein. (D-SPA). SPA is a C-terminal tag that is 
used to purify a target protein with its corresponding antibody (Zeghouf et al. 2004). Interestingly, the 
D-GFP and D-CAP fusions could be expressed constitutively without compromising host viability, 
whereas D-SPA expression reduced cell viability by >50-fold. These results suggest that not all 
fusions are well tolerated. Termed “recalcitrant” such fusions prevent protein oligomerization and the 
formation of trimers during phage assembly and therefore display fewer D-fusion proteins. Overall, 
this group was successful in creating three different D-fusions, where the D-GFP was highly 
fluorescent, the D-SPA was recognized by a FLAG monoclonal antibody and the D-CAP construct 
was able to elicit both an antigen-specific cellular and humoral response in pigs. One important note 
to make though, is that once these constructs were integrated into a lambda display particle (LDP) 
both LDP-D-GFP and LDP-D-SPA did not induce a useful antibody response suggesting that in vivo 
they would not elicit a sufficient immune response (Hayes, Gamage & Hayes 2010, Gamage, Ellis & 
Hayes 2009). With the ability to control the number of fusions present, the chance of encountering 
recalcitrant fusions would be decreased. Despite the lower number of fusions per phage, cell viability 
would be improved.  
The issue of “recalcitrant” protein display was explored in detail by Zanghi et al. (2005) who 
developed a mosaic expression approach where λ was decorated by both wild-type and recombinant 
proteins in tandem to circumvent the issue of recalcitrance. This system utilized two separate plasmid 
constructs that contained different origins of replication and selectable markers, that were co-
transformed into a gpD-deficient λ lysogen. When only the recombinant plasmid was expressed no 
viable phage could be recovered, indicating that the fusion must somehow interfere with assembly or 
prevent formation of stable phage particles. Mosaic phage titres were very similar to that of wild-type 
phage, where the slight reduction could be attributed to plasmid attributes—mainly copy number and 
protein expression (Zanghi et al. 2005). With the presence of two plasmids that theoretically have 
consistent expression and fusion capacities, the level of control is still quite limited. In contrast, 
employing an independent second dimension of control such as that conferred by suppression, 
imparts differences in rates of incorporation due to functionality that can generate greater variability 
in decoration.  
This group next expanded on this design by using the same construct design to 
simultaneously fuse proteins to both the head and tail of λ. The proteins that were tested were 
intended to increase phage-mediated gene transfer into mammalian cells. In order to utilize phage 
during gene transfer, phage will need to be able to overcome multiple intracellular barriers such as 
“cell attachment, cytoplasmic entry, endosomal escape, uncoating and nuclear import”. Using this 
strategy, multiple peptides could be displayed in tandem, with each function to circumvent a separate 
barrier. During this process they were also able to determine that the number of fusions per phage 
particle was roughly 400 copies for gpD and 100 copies for gpV (Zanghi et al. 2007). In addition to 
using a system like this to overcome intracellular barriers, this system could potentially be employed 
to target intracellular pathogens, where the lower density display would presumably be employed for 
ligand interaction and receptor-mediated endocytosis, while a higher density display could be used to 
target the pathogen specifically.   
 A more recent and commercial example of phage display employed λ phage scaffold 
decorated with HIV-1 envelope protein gp140 via in vitro complementation. The immune response 
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elicited was then compared to that of soluble gp140. This strategy was employed because in their 
native state, envelope spike proteins are sparsely present on the virion and the ability to increase their 
density on the phage capsid, would in theory generate an increased immune response. Phage were 
decorated with a mixture (different molar ratios) of gpD:gp140 and wild-type gpD protein. Like 
Zanghi et al. (2005) and Hayes et al. (2010), Mattiacio et al. (2011) also discovered that phage were 
“recalcitrant” and not stable when decorated completely or with a 20-fold molar excess of fusion 
protein. Further to this, they also determined that some fusion proteins could stabilize phage particles 
even when they occupy only a fraction of the gpD binding sites. It was determined that the number of 
fusions incorporated into the capsid was 30 copies of Env trimers per particle. In regards to immune 
response, the authors did not observe an increased response to the decorated phage as compared to the 
conventional protein (Mattiacio et al. 2011). This shortfall may have been circumvented by the 
system described here, whereby utilizing a weak suppressor could have increased the number of 
fusions per particle. This in turn could have elicited a stronger immune response than what was 
observed with the conventional protein. Each of these groups also executed codon optimization in 
developing their constructs. This allowed for more efficient protein expression and decreased the 
homology of fusions to native λ sequences, thus decreasing the potential for homologous 
recombination between alleles (Zanghi et al. 2005).    
4.2.1.2 Use of Phage in Gene Transfer 
An early use of filamentous phage for gene transfer and delivery was first reported by Hart et al. 
(1994). In this study, phage fd was employed to display a cyclic-binding peptide sequence via 
translational fusion to major coat protein pVIII. This N-terminal fusion was shown to bind to cells 
and be efficiently internalized where competition and cell binding assays, staining and different forms 
of microscopy detected cell binding. Approximately 300 copies of fusion protein were present per 
phage (Hart et al. 1994). The same peptide sequence was then fused to the major tail protein. 
hypothesizing that λ is a more suitable candidate for transfecting mammalian cells. The double 
stranded DNA genome of λ would be more effective in cell transfection compared to single-stranded 
filamentous phage DNA that would need to be converted to double-stranded. These modified phage 
were shown to transfect mammalian cells at a remarkable frequency as compared to the control 
counterparts that showed no significant interaction with cells. (Dunn 1996).    
 Lankes et al. (2007) expanded the application of lambda as a gene or vaccine delivery vector 
by executing phage-mediated gene transfer in vivo. They constructed recombinant λ particles 
encoding firefly luciferase, in order to visualize gene delivery in real-time via the use of 
bioluminescence imaging (Xenogen IVIS system). They also determined that pre-immunization of 
mice with wt λ, a few weeks before immunization with recombinant phage conferred increased 
luciferase expression compared to unprimed control mice (Lankes et al. 2007). They next fused a 
αvβ3 (CD51/CD61) receptor integrin-binding peptide to gpD to increase its uptake by receptor-
mediated pinocytosis. This integrin was chosen because it is known to play a role in the 
binding/internalization of a number of mammalian viruses and it also has been previously used to 
enhance the targeting of modified virus vectors to dendritic cells, a particularly useful accessory cell 
target for a vaccine vector. Through the use of this recombinant phage, the study showed an increased 
internalization versus a nonfused phage, where internalization was decreased in a dose-dependent 
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fashion; similar to findings by Vaccaro et al., (2006) who noted a similar decrease in internalization 
upon addition of competitor protein, indicating a receptor-mediated process. The recombinant phage 
outperformed the control cells both in vitro and in vivo. In addition, there was a 100-fold increase in 
the efficiency of phage internalization into integrin positive cells vs. control cells, but only about a 3-
fold increase in the level of phage-mediated gene expression, suggesting that an increase in 
internalization does not correspond to a comparable increase in delivery of genetic material. Overall, 
this study provided a proof-of-concept for the use of recombinant phage to increase the gene transfer 
in vivo and also provides compelling argument for the use of phage in transgene delivery (Lankes et 
al. 2007)         
 Sapinoro et al. (2008) further explored pre-immunization as an approach to increase the 
uptake of recombinant phage, termed antibody-dependent enhancement. In concept, as “virus-specific 
antibodies fail to completely neutralize virus infectivity, the opsonization instead permits the more 
efficient infection of susceptible host cells such as monocytes and macrophages”. The group’s goal 
was to develop an in vitro model for this phenomenon in mammalian cells by bacteriophage λ vectors 
and determine their mechanisms. Since it is known that this effect can be mediated through cellular 
receptors specific for the Fc portion of IgG, the group used a cell line expressing human Fc gamma 
receptor (FcγR) receptor. The conclusions of this study indicated that antibody-dependent 
enhancement of phage-mediated gene transfer requires a receptor on the surface of target cells. In 
addition, prior immunization with wild-type phage results in more efficient phage-mediated gene 
expression in live mice and this increased transduction is undertaken through a receptor-mediated 
endocytic mechanism rather than through phagocytosis (Sapinoro et al. 2008).  
 Overall, the system created by this research study has many advantages for use in 
development of downstream vaccines and targeted gene therapy approaches. When undertaking a 
vaccination approach high-density display may be preferable as functionality of the fused protein may 
not be critical. In contrast, an application such as targeted gene therapy relies upon ligand interaction 
and proper folding/function of the fusion to improve cell specificity or enhanced endocytosis. The 
ability to control the number of fusions provides power and flexibility to cater mosaic phage to 
different scenarios and needs. Moreover, the ability to control the number of fusions and gpD 
molecules could reduce the chance of recalcitrance and improve viability. Finally, this system can 
further be expanded to generate multiple fusions, and polyvalent therapeutics.   
4.3 Future Experimentation (Next Steps) 
In order to further increase the likelihood and applicability of this research moving forward, necessary 
future experimentation is outlined below. During the preparation of this thesis, new work in our lab 
has been carried out that addresses many of the next steps indicated here. In progress or complete 
work directly related to the future steps outlined here has been inserted into Appendix A with 
description.  
1. Additional plating experiments to confirm the viability of phage and varying levels of D:GFP 
expression; more effective means of phage preparation are required due to the occurrence of 
low titres when using traditional lysate preparation methods (CsCl, PEG precipitation, large 
volume batch cultures).  
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• Table 2 of Appendix A shows a continuation of this work. As noted in my work here, the 
greatest viability (eop) was again observed for the strong suppressors grown at low 
temperatures and 37° C is the ideal temperature for growth on a weak (SupD) or 
nonsuppressor strain. These additional results follow the same trends as those observed 
during the initial experimentation of this study.  
2. Determination of a more effective way to quantify the number of GFP fusions present per 
phage capsid under varying conditions. This may include the use of an antibody-based 
approach (ELISA, Western Blot) or potentially the use of a more specific measurement 
instrument such as Fluorescence Activated Cell Sorting (FACS), FCS or photon 
antibunching. Once a more effective measurement of fusions can be determined, further 
experiments can be designed to determine if phage are viable and if populations are 
heterogeneous or homogenous.  
• To compare fluorescence of phage from various preparations, flow cytometry 
experiments were performed for SupE (Sokolenko et al. 2012) as well as other strains 
(Table 4 of Appendix A). As expected the weak suppressor (SupD) and the 
nonsuppressor strains again show the highest level of decoration. In addition, for all 
species examined, the greatest decoration was recorded at the optimal temperature of 37° 
C, which is on point, with all previous studies.  
3. Further investigation into inner filtering when high-density display is achieved with GFP. If 
this phenomenon is observed, qualitative fluorescence measurements may need to be adjusted 
(Scholz et al. 2000).  
• This work has yet to be completed, but further fluorescent work through the use of FACS 
has continued to follow expected trends. This being said, there could still be an 
underestimation of the level of fluorescence emitted by each phage particle. Because 
more quantitative approaches have been taken to count the number of fusions per phage, 
this potential phenomenon becomes more relevant in helping to determine if fusion-to-
fusion interactions occur between and within phage particles, which could be very useful 
information when employing alternative fusions for downstream applications.   
4. Supplementary exploration into the supD expression system, as the use of this cell and a 
mosaic approach (fusion and wild-type) may be the most effective way to achieve nearly 
100% display with fusions, when large recalcitrant proteins are desired for display.  
• This work has yet to be completed, but will pose an interesting task and a very important 
one in determining the future potential of this work and how relevant it will be to 
specifically the development of vaccines. Further exploration into the ability for high-
density (maximal display) becomes a very important caveat to the development of 
vaccines and the ability to elicit an appropriate immune response. In relation to this, it 
will also be important to further explore this specific expression, as it will not only help 
to indicate the level of display possible, but may also give insight into any restrictions 
that exist as to the type and size of peptide/protein that can be fused to gpD as traditional 
recalcitrance may be able to be eliminated for some fusions.  
• Tables 5 and 6 in Appendix A show sizing of phage grown on different strains. 
Interestingly, when phage are complemented with wild type gpD, all suppressor strains 
are relatively the same size, whereas the nonsuppressor strain is significantly larger, 
 
  65 
which may be because no suppressor is present and therefore gpD is incorporated more 
efficiently, with no effect on assembly or viability. Correspondingly, when size 
comparisons are made between decorated phage (Table 6), considerable differences are 
seen not only between phage preparations on the various suppressors strains, but as 
expected, particles are much larger than their non-decorated counterparts. As in this 
work, 37° C again confers the ideal temperature for fusion, regardless of bacterial strain, 
but unlike the wild type complementation, the SupD and nonsuppressor strain phage 
preparations lead the pack, with once again, the nonsuppressor showing the greatest 
diameter.  
5. Forrer and Jaussi (1998), produced a His-tagged derivative of gpD, they named gpHD. This 
fusion partner is seen to be able to mediate optimal translation initiation while reducing 
inclusion body formation and protein degradation, making it an ideal fusion partner for high-
level expression of soluble heterologous protein in the cytoplasm of E. coli. The authors 
believe in order to do this gpHD acts as a “cytoplasmic anchor”, allowing its fusion partner 
more time to fold which decreases the likelihood of aggregation and degradation (Forrer, 
Jaussi 1998). Similar incremental improvements could be made to future gpD fusion 
constructs taking into account advantageous modifications that increase the functionality and 
create optimal conditions for each individual fusion protein. 
• In addition to exploring other incremental improvements to optimize this system, it is 
also important to explore appropriate applications and fusion partners as eGFP was 
employed for exploration and optimization purposes only. One application currently 
being characterized in our lab is the expression of S. aureus endolysin on the phage 
capsid to serve as a bacteriolytic therapeutic against Staphylococcal infections. 	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Appendix A Supplementary Data 
The data below is supplementary and is part of a current paper that is in draft form within our lab. 
Nicastro, J., Sheldon, K., Kaur, T., Aucoin, M., and R.A. Slavcev*. 2013. Construction and 
development of a fine-tuned lytic phage display system. Applied Microbiology and Biotechnology.    
Table 2. Variable amber suppression and complementation of the Dam15 mutation 
Relative efficiency of plating (eop) 3  Strain 1 / 
Plasmid 2 30o C 32-33 o C 35 o C 37 o C 39-40 o C 
Sup-    
   pD— 
   pD+ 
   pD::eGFP 
nd 
4.06 x 10-6 
7.5 x 10-6 
7.5 x 10-6 
nd 
5.0 x 10-6 
3.2 x 10-5 
2.0 x 10-5 
nd 
3.1x 10-6 
2.1 x 10-4 
2.0 x 10-5 
1.92 x 10-6 








   pD— 
   pD::eGFP 
nd 
8.8 x 10-5 
4.9 x 10-5 
nd 
6.5 x 10-5 
1.8E-5 
nd 
1.5 x 10-5 
8E-5 
1.13 x 10-5 
9.5 x 10-6 
0.09 
nd 
2.3 x 10-5 
0.05 
SupE 
   pD— 




























   pD::eGFP 0.1 0.13 0.06 0.07 0.05 
1 Derivatives are W3101 background. 
2 Derivatives of CI857 temperature regulated expression plasmid pPL451. 
3 All eop determinations from a minimum of three assay and determined using BB4 (SupE, SupF) as 
the 100% control. 
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Table 4. Estimated average eGFP molecules per phage. 
Estimated eGFP/phage 2  Strain (+/- Plasmid) 1 
30oC 35oC 37oC 39oC 
Sup— [pD::eGFP] n/a 44 ± 2 115 ± 6 61 ± 10 
SupD  [pD::eGFP] 86 ± 19 127 ± 5 147 ± 33 142 ± 25 
SupE  [pD::eGFP] 46 ± 15 53 ± 5 77 ± 1 69 ± 1 
SupF  [pD::eGFP] 65 ± 1 69 ± 89 ± 2 69 ± 5 
1 all strains are derivatives of W3101. 
2 fluorescence measurements were divided by those derived from λF7 grown on that strain. Values in 
parentheses denote calculated number of functional eGP fusions per phage interpolated from eGFP 
purified protein fluorescence calibration curve. 
3 Phage preparation on W3101[pD] at 37oC expressing gpDwt in trans 
Table 5. Sizing of λ Dam15 phage grown on suppressor strain series 
Strain 1 gpD Allele Relative size difference 2 
Sup—   3 gpDwt 1.1 ± 0.2 
SupE gpDwt 1.0 
SupD   gpDQ68S 0.3 ± 0.1 
SupF   gpDQ68Y 0.6 ± 0.3 
1 All strains are derivatives of W3101 
2 A minimum of three runs of triplicate determinations of size determination from DLS were divided 
by size determinations for phage generated of W3101 supE, conferring the Dwt allele decoration of 
λDam15 phage in absence of complementation.  
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3 Phage preparation on W3101[pD] at 37oC expressing gpDwt in trans 
Table 6. Sizing of λ Dam15 phage variably decorated by gpD::eGFP  
Times (X) increase in phage diameter 2 Strain [+ Plasmid] 1 
30oC 35oC 37oC 39oC 
Sup—    




2.2 ± 0.5 
n/a 
5.5 ± 0.8 
nd 
3.5 ± 0.9 
SupD  
SupD  [pD::eGFP] 
nd 
0.8 ± 0.1 
nd 
1.2 ± 0.7 
0.3 ± 0.03 
3.1 ± 1.5 
nd 
1.8 ± 0.2 
SupE  
SupE  [pD::eGFP] 
nd 
0.9 ± 0.2 
nd 
1.0 ± 0.1 
1.0 ± 0.1 
1.7 ± 0.2 
nd 
1.2 ± 0.2 
SupF  
SupF  [pD::eGFP] 
nd 
1.0 ± 0.3 
nd 
1.3 ± 0.2  
0.67 ± 0.3 
1.6 ± 0.6 
nd 
1.0 ± 0.3 
1 Lysate produced on strain at respective temp. All strains are derivatives of W3101. 
2 A minimum of three runs of triplicate determinations of size determination from DLS were divided 
by size determinations for naked phage grown on each of the Sup strains. Comparisons are for phage 
grown on SupE in absence of complementation. 
3 nd, not done 
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